{"gene":"PTEN","run_date":"2026-04-28T19:45:45","timeline":{"discoveries":[{"year":1997,"finding":"PTEN was identified as a candidate tumor suppressor gene at chromosome 10q23, encoding a protein with a protein tyrosine phosphatase domain and extensive homology to the cytoskeletal protein tensin, suggesting it may suppress tumor growth by antagonizing protein tyrosine kinases and regulating focal adhesions.","method":"Positional cloning, homozygous deletion mapping, mutation screening in cancer cell lines","journal":"Science","confidence":"High","confidence_rationale":"Tier 1 — original cloning paper, replicated independently by MMAC1 identification","pmids":["9072974"],"is_preprint":false},{"year":1997,"finding":"PTEN (MMAC1) encodes a protein with homology to the catalytic domain of protein phosphatases and to cytoskeletal proteins tensin and auxilin; mutations were identified in glioma, prostate, kidney, and breast carcinoma cell lines/specimens.","method":"Positional cloning, homozygous deletion mapping, sequence analysis","journal":"Nature genetics","confidence":"High","confidence_rationale":"Tier 1 — independent isolation of the same gene, orthogonal cloning strategy","pmids":["9090379"],"is_preprint":false},{"year":1997,"finding":"TEP1 (identical to PTEN/MMAC1) possesses intrinsic protein tyrosine phosphatase activity; it is a cytoplasmic protein sharing homology with tensin and auxilin, and its expression is down-regulated by TGF-β.","method":"Biochemical phosphatase assay, immunofluorescence, Northern blot, chromosomal mapping","journal":"Cancer research","confidence":"High","confidence_rationale":"Tier 1 — direct enzymatic activity demonstrated in vitro, subcellular localization by immunofluorescence","pmids":["9187108"],"is_preprint":false},{"year":1997,"finding":"Germline mutations in PTEN cause Cowden disease; mutations are found throughout the gene and predicted to disrupt the protein tyrosine/dual-specificity phosphatase domain, establishing PTEN as a tumor suppressor in the germline.","method":"Germline mutational analysis of Cowden disease kindreds","journal":"Nature genetics","confidence":"High","confidence_rationale":"Tier 2 — germline mutation analysis in multiple families, replicated by multiple groups","pmids":["9140396"],"is_preprint":false},{"year":1998,"finding":"PTEN dephosphorylates phosphatidylinositol 3,4,5-trisphosphate (PtdIns(3,4,5)P3) specifically at position 3 on the inositol ring; overexpression reduces insulin-induced PtdIns(3,4,5)P3, while the catalytically inactive C124S mutant causes PtdIns(3,4,5)P3 accumulation. PTEN also exhibits 3-phosphatase activity toward inositol 1,3,4,5-tetrakisphosphate.","method":"In vitro phosphatase assay with purified recombinant PTEN, transfection of wild-type and C124S mutant in 293 cells, lipid measurement","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 — reconstituted in vitro with purified protein and active-site mutagenesis, foundational mechanism paper","pmids":["9593664"],"is_preprint":false},{"year":1998,"finding":"The lipid phosphatase activity of PTEN is critical for its tumor suppressor function: a Cowden disease missense mutation (G129E) specifically ablates recognition of inositol phospholipid substrates without affecting protein phosphatase activity; wild-type PTEN expression in PTEN-deficient tumor cells inhibits PKB/Akt and regulates cell survival.","method":"In vitro lipid phosphatase assay, cell-based PIP3 measurement, PKB/Akt phosphorylation assay, ectopic expression in tumor cell lines","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1 — substrate-specific mutagenesis distinguishing lipid from protein phosphatase activity, functional rescue experiment","pmids":["9811831"],"is_preprint":false},{"year":1998,"finding":"PTEN inhibits cell migration, integrin-mediated cell spreading, and the formation of focal adhesions; PTEN interacts with focal adhesion kinase (FAK) and reduces FAK tyrosine phosphorylation; overexpression of FAK partially antagonizes PTEN effects; the phosphatase domain is required for these effects.","method":"Cell migration assay, focal adhesion staining, co-immunoprecipitation, FAK phosphorylation assay, PTEN overexpression and antisense","journal":"Science","confidence":"High","confidence_rationale":"Tier 1–2 — multiple orthogonal functional assays with phosphatase-dead mutant control and reciprocal IP","pmids":["9616126"],"is_preprint":false},{"year":1998,"finding":"Pten is essential for embryonic development; homozygous Pten knockout mice die early in embryogenesis; heterozygous mice develop hyperplastic-dysplastic changes and spontaneous tumors, demonstrating Pten is a bona fide tumor suppressor gene in vivo.","method":"Homologous recombination knockout in mice, histopathology, tumor analysis","journal":"Nature genetics","confidence":"High","confidence_rationale":"Tier 2 — in vivo mouse genetic model with rigorous phenotypic characterization, replicated by multiple labs","pmids":["9697695"],"is_preprint":false},{"year":1999,"finding":"Crystal structure of PTEN reveals a phosphatase domain with an enlarged active site accommodating phosphoinositide substrates, and a C2 domain that binds phospholipid membranes in vitro; mutation of basic residues in the C2 domain reduces membrane affinity and tumor cell growth suppression.","method":"X-ray crystallography, lipid binding assay, mutagenesis, cell growth assay","journal":"Cell","confidence":"High","confidence_rationale":"Tier 1 — crystal structure with functional validation by mutagenesis and membrane binding assay","pmids":["10555148"],"is_preprint":false},{"year":1999,"finding":"PTEN directly dephosphorylates and inhibits focal adhesion kinase (FAK), thereby negatively regulating signals generated at focal adhesions; PTEN also inhibits the adaptor protein Shc to negatively regulate growth factor receptor signaling.","method":"In vitro phosphatase assay, co-immunoprecipitation, Western blot analysis of FAK phosphorylation","journal":"European journal of biochemistry","confidence":"Medium","confidence_rationale":"Tier 2–3 — review synthesizing experimental evidence, citing in vitro assays and co-IP from primary papers","pmids":["10469123"],"is_preprint":false},{"year":2000,"finding":"PTEN PDZ binding domain (C-terminal) interacts with PDZ domains of hDLG and hMAST205; threonine phosphorylation of the PTEN PDZ binding domain inhibits interaction with hDLG and hMAST205 PDZ domains but promotes interaction with ~90 kDa and ~120 kDa proteins from cell lysates.","method":"Yeast two-hybrid, microtiter plate binding assay, peptide coprecipitation from cell lysates, Western blotting","journal":"Cancer research","confidence":"Medium","confidence_rationale":"Tier 2–3 — yeast two-hybrid plus cell lysate coprecipitation with phosphopeptide modulation","pmids":["10646847"],"is_preprint":false},{"year":2001,"finding":"PTEN suppresses Bcl-2 expression via its lipid phosphatase activity acting through the Akt/CREB pathway; PTEN reduces Bcl-2 mRNA and protein, downregulates Bcl-2 promoter activity through decreased CREB phosphorylation at Ser133, and loss of PTEN leads to chemoresistance that is rescued by Bcl-2 overexpression.","method":"Transfection, RT-PCR, Western blot, Bcl-2 promoter-reporter assay, cell death assay","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 — multiple orthogonal assays in single lab with lipid-phosphatase-dead mutant controls","pmids":["11495901"],"is_preprint":false},{"year":2001,"finding":"p53 transcriptionally activates PTEN through a p53 binding element directly upstream of the PTEN gene; PTEN is required for p53-mediated apoptosis in immortalized mouse embryonic fibroblasts, placing PTEN downstream of p53 in a tumor suppressor signaling axis.","method":"Deletion and mutation analysis of PTEN promoter, p53 induction assays, mRNA measurement, apoptosis assay in PTEN-null MEFs","journal":"Molecular cell","confidence":"High","confidence_rationale":"Tier 2 — promoter deletion/mutation analysis plus genetic epistasis in MEFs","pmids":["11545734"],"is_preprint":false},{"year":2002,"finding":"PTEN is reversibly inactivated by H2O2 through formation of an intramolecular disulfide bond between the catalytic Cys124 and Cys71; thioredoxin, not glutaredoxin or glutathione, is the primary cellular reductant that restores PTEN activity; thioredoxin co-immunoprecipitates with PTEN from cell lysates.","method":"Purified PTEN oxidation assay, mass spectrometry of tryptic peptides, cysteine mutant analysis, co-immunoprecipitation, inhibitor studies in cells","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 — in vitro biochemistry with mass spectrometry identification of disulfide, corroborated by co-IP and cell-based inhibitor studies","pmids":["11916965"],"is_preprint":false},{"year":2004,"finding":"PTEN negatively regulates MDM2 transcription by suppressing its P1 promoter activity through its lipid phosphatase activity (independent of p53), thereby reducing L-Mdm2 expression and p90(MDM2) isoform production.","method":"Reporter assays, RT-PCR, Western blot, lipid phosphatase-dead PTEN mutant analysis, Pten-null cell lines and prostate cancer tissues","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 — reporter assay with phosphatase-dead mutant controls in multiple cell contexts","pmids":["15090541"],"is_preprint":false},{"year":2006,"finding":"PCAF histone acetyltransferase physically interacts with PTEN and acetylates Lys125 and Lys128 within the catalytic cleft of PTEN in a growth factor-dependent manner; acetylation of these residues inhibits PTEN's ability to down-regulate PI3K signaling and induce G1 cell cycle arrest; acetylation-resistant K125R/K128R PTEN mutants retain PI3K regulatory activity even with forced PCAF expression.","method":"Co-immunoprecipitation, acetylation assay, shRNA knockdown of PCAF, cell cycle analysis, PI3K signaling measurement, site-directed mutagenesis","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1–2 — physical interaction, enzymatic modification, mutagenesis of modification sites, and functional rescue, multiple orthogonal methods","pmids":["16829519"],"is_preprint":false},{"year":2007,"finding":"Nuclear PTEN is essential for chromosomal integrity; PTEN localizes at centromeres and physically associates with CENP-C; disruption of Pten leads to centromere breakage and chromosomal translocations; PTEN regulates Rad51 expression to reduce spontaneous DNA double-strand breaks.","method":"Chromosome analysis, co-immunoprecipitation of PTEN with CENP-C, immunofluorescence localization, Rad51 expression analysis, Pten-null cells","journal":"Cell","confidence":"High","confidence_rationale":"Tier 2 — physical association by co-IP, localization by immunofluorescence, and defined chromosomal phenotype in knockout cells","pmids":["17218262"],"is_preprint":false},{"year":2008,"finding":"PTEN exists as a monomer or as part of a >600-kDa PTEN-associated complex (PAC); PTEN associates with p85, the regulatory subunit of PI3K, and the p110β isoform of PI3K; this association involves unphosphorylated PTEN within the PAC and is enhanced by trastuzumab treatment.","method":"Gel filtration, co-immunoprecipitation with specific antibodies, AKT phosphorylation assay, trastuzumab treatment","journal":"Molecular and cellular biology","confidence":"Medium","confidence_rationale":"Tier 2–3 — gel filtration to define complex, reciprocal co-IP, functional correlation with AKT signaling","pmids":["19635806"],"is_preprint":false},{"year":2008,"finding":"PTEN activity is regulated by its C-terminal tail phosphorylation: when phosphorylated, the unstructured C-terminal tail interacts with the phosphatase-C2 superdomain to inactivate PTEN by preventing membrane association; oxidation of the active site cysteine by ROS and C-terminal Ser/Thr phosphorylation inhibit PTEN and regulate its stability and localization.","method":"Biochemical assays, mutagenesis, membrane association assays, review of structural and regulatory data","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 — synthesizes experimental data on mechanism of autoinhibition, backed by mutagenesis and membrane assays","pmids":["18794881"],"is_preprint":false},{"year":2008,"finding":"PTEN enters the nucleus by multiple mechanisms including simple diffusion, active shuttling, cytoplasmic-localization-signal-dependent export, and monoubiquitylation-dependent import; nuclear PTEN has phosphatase-independent roles in chromosome stability, DNA repair, and cell cycle arrest distinct from cytoplasmic PTEN.","method":"Review of experimental data including nuclear localization studies, ubiquitylation assays, and chromosome stability assays","journal":"Journal of cell science","confidence":"Medium","confidence_rationale":"Tier 2–3 — review synthesizing direct experimental evidence on nuclear localization mechanisms and function","pmids":["18216329"],"is_preprint":false},{"year":2008,"finding":"A novel Akt-EGR1-ARF-PTEN axis exists in which PTEN transcriptional activation requires p14ARF-mediated sumoylation of EGR1; Akt phosphorylates EGR1 at S350 and T309, promoting EGR1 interaction with ARF and subsequent sumoylation at K272; ARF-deficient mice exhibit reduced PTEN, establishing a regulatory circuit.","method":"In vivo sumoylation assay, co-immunoprecipitation, site-directed mutagenesis, ARF-null mouse analysis, Western blot","journal":"The EMBO journal","confidence":"Medium","confidence_rationale":"Tier 2 — in vivo sumoylation, mutagenesis, and genetic model corroboration in single study","pmids":["19057511"],"is_preprint":false},{"year":2013,"finding":"USP13 is a deubiquitylase that stabilizes PTEN by direct binding and deubiquitylation; USP13 loss in breast cancer cells promotes AKT phosphorylation and tumorigenesis through PTEN downregulation; USP13 overexpression suppresses tumorigenesis only in PTEN-positive cells.","method":"DUB screen (30 DUBs tested), co-immunoprecipitation, ubiquitylation assay, cell proliferation and tumor growth assays, human breast tumor correlation","journal":"Nature cell biology","confidence":"High","confidence_rationale":"Tier 2 — systematic screen, direct binding, deubiquitylation assay, genetic functional validation in cells and in vivo","pmids":["24270891"],"is_preprint":false},{"year":2014,"finding":"Tankyrases (PARP family members) interact with PTEN, poly-ADP-ribosylate it, and promote its recognition by the PAR-binding E3 ubiquitin ligase RNF146, leading to PTEN ubiquitination and proteasomal degradation; tankyrase knockdown stabilizes PTEN and suppresses AKT signaling, cell proliferation, and tumor growth.","method":"Co-immunoprecipitation, ADP-ribosylation assay, ubiquitination assay, tankyrase knockdown, AKT phosphorylation assay, in vivo tumor model","journal":"Genes & development","confidence":"High","confidence_rationale":"Tier 1–2 — new PTM identified with biochemical assays, E3 ligase identified, functional in vivo validation","pmids":["25547115"],"is_preprint":false},{"year":2015,"finding":"PTEN is physically associated with replication protein A 1 (RPA1) via the RPA1 C-terminal domain; PTEN localizes at replication sites (shown by iPOND) and promotes RPA1 accumulation on replication forks; PTEN recruits the deubiquitinase OTUB1 to mediate RPA1 deubiquitination; PTEN deletion leads to replication fork collapse under hydroxyurea-induced stress.","method":"Co-immunoprecipitation, iPOND, STORM super-resolution imaging, deubiquitylation assay, replication fork analysis","journal":"Cell research","confidence":"High","confidence_rationale":"Tier 1–2 — multiple orthogonal methods (iPOND, STORM, co-IP, biochemical assay) in one study","pmids":["26403191"],"is_preprint":false},{"year":2015,"finding":"AIF (apoptosis-inducing factor) physically interacts with PTEN and protects it from oxidation-mediated inactivation; PTEN is identified as a mitochondrial protein; AIF knockdown causes PTEN lipid phosphatase inactivation, AKT activation, and promotes epithelial-mesenchymal transition through β-catenin signaling.","method":"Co-immunoprecipitation, lipid phosphatase activity assay, oxidation assay, mitochondrial fractionation, in vitro and in vivo tumor metastasis models","journal":"EMBO reports","confidence":"Medium","confidence_rationale":"Tier 2 — physical interaction, enzymatic activity measurement, subcellular fractionation, functional in vivo model","pmids":["26415504"],"is_preprint":false},{"year":2015,"finding":"PTEN physically associates with TOP2A (DNA topoisomerase IIα) and stabilizes it through OTUD3 deubiquitinase; PTEN deficiency leads to TOP2A downregulation, dysfunction of the decatenation G2 checkpoint, and incomplete DNA decatenation causing ultra-fine anaphase bridges.","method":"Co-immunoprecipitation, ubiquitination assay, ultra-fine bridge (UFB) analysis, decatenation checkpoint assay, PTEN-null cell analysis","journal":"Scientific reports","confidence":"Medium","confidence_rationale":"Tier 2 — physical interaction by co-IP, enzymatic stability mechanism, defined chromosomal phenotype","pmids":["26657567"],"is_preprint":false},{"year":2016,"finding":"PTEN physically associates with PLK1 (polo-like kinase 1) and reduces PLK1 phosphorylation in a protein phosphatase-dependent manner; PTEN deficiency leads to PLK1 hyperphosphorylation and polyploidy; a phospho-mimicking PLK1 mutant causes polyploidy, and a non-phosphorylatable PLK1 mutant rescues the polyploid phenotype.","method":"Co-immunoprecipitation, phosphatase assay, cell cycle analysis (polyploidy), site-directed mutagenesis of PLK1","journal":"Cell cycle","confidence":"Medium","confidence_rationale":"Tier 2 — physical interaction, phosphatase-dependent functional change, genetic rescue with mutant PLK1","pmids":["27398835"],"is_preprint":false},{"year":2017,"finding":"PARK2 depletion leads to AMPK-mediated activation of eNOS, increased reactive oxygen species and oxidized nitric oxide, resulting in PTEN inhibition by S-nitrosylation and subsequent ubiquitination; AMPK activation alone is sufficient to induce PTEN S-nitrosylation, linking energy stress to PTEN suppression.","method":"S-nitrosylation assay, AMPK activation, eNOS inhibition, ubiquitination assay, PI3K/Akt signaling measurement, in vivo cooperativity in Park2/Pten mouse model","journal":"Molecular cell","confidence":"High","confidence_rationale":"Tier 1–2 — biochemical demonstration of S-nitrosylation, identification of upstream pathway, genetic validation in vivo","pmids":["28306514"],"is_preprint":false},{"year":2019,"finding":"PTEN directly interacts with and dephosphorylates autophosphorylated PGK1 (at Y324) via its protein phosphatase activity, thereby inhibiting PGK1 kinase activity, glycolysis, and ATP production in brain tumor cells; PGK1-Y324F knockin mice show reduced brain tumor formation.","method":"Co-immunoprecipitation, in vitro phosphatase assay, PGK1 Y324 phosphorylation analysis, glycolysis measurement, knockin mouse model, human GBM specimen analysis","journal":"Molecular cell","confidence":"High","confidence_rationale":"Tier 1 — direct substrate identification, in vitro reconstitution, mutagenesis, and in vivo knockin validation","pmids":["31492635"],"is_preprint":false},{"year":2019,"finding":"PTEN inhibits ARID4B expression, while ARID4B is a transcriptional activator of PI3K subunit genes PIK3CA and PIK3R2; reciprocal binding of ARID4B and histone H1 to PIK3CA and PIK3R2 promoters modulates chromatin condensation; ARID4B is required for prostate tumorigenesis when PTEN is deficient.","method":"ChIP, promoter analysis, gene expression assays, functional tumorigenesis assays, patient cohort correlation","journal":"Nature communications","confidence":"Medium","confidence_rationale":"Tier 2 — ChIP, functional tumorigenesis assays, mechanistic pathway identification in single study","pmids":["31551414"],"is_preprint":false},{"year":2020,"finding":"FBXO22 induces ubiquitylation specifically of nuclear (not cytoplasmic) PTEN at lysine 221, targeting it for proteasomal degradation; FBXO22 acts as a tumor promoter by degrading nuclear PTEN, and is overexpressed in various cancer types.","method":"Co-immunoprecipitation, ubiquitylation assay, site-directed mutagenesis (K221), nuclear/cytoplasmic fractionation, functional tumor assays","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 1–2 — specific ubiquitylation site identified by mutagenesis, compartment-specific effect established by fractionation, functional tumor assays","pmids":["32249768"],"is_preprint":false},{"year":2020,"finding":"The carboxy-terminal tail (CTT) of PTEN, when phosphorylated, interacts with the phosphatase-C2 superdomain to prevent membrane association and inactivate the enzyme; alternate translation-initiation generates extended PTEN isoforms (e.g., PTEN-L) with a signal sequence, polyarginine motif, and membrane-binding helix that activates the enzyme and facilitates mitochondrial and nucleolar localization.","method":"Structural analysis, biochemical membrane association assays, isoform characterization, mutagenesis","journal":"Cold Spring Harbor perspectives in medicine","confidence":"Medium","confidence_rationale":"Tier 2 — structural and biochemical evidence for CTT autoinhibition; isoform characterization with functional annotation","pmids":["31636093"],"is_preprint":false},{"year":2021,"finding":"Physiological and oncogenic PI3K pathway activation increases PTEN expression via mTOR/4E-BP1-dependent translational control; deletion of 4E-BP1 abolishes this translational regulation; this constitutes a homeostatic feedback loop limiting pathway duration and contributing to rebound activation upon PI3K inhibitor treatment.","method":"PI3K inhibitor treatment, 4E-BP1 deletion, translational rate measurement, in vitro and in vivo PI3K signaling assays","journal":"Molecular cell","confidence":"High","confidence_rationale":"Tier 2 — genetic deletion of 4E-BP1 establishes mechanism, pharmacologic and oncogenic contexts tested","pmids":["33606974"],"is_preprint":false},{"year":2021,"finding":"Peroxiredoxin I (Prx I) directly interacts with PTEN and protects it from oxidation under mild oxidative stress, preserving PTEN tumor-suppressive function; Prx II-deficient cells show increased PTEN oxidation and insulin sensitivity; Prx III protects PTEN from oxidation by pro-oxidant lipid mediators.","method":"Co-immunoprecipitation, PTEN oxidation assay, Prx-deficient cell lines, insulin signaling measurement","journal":"Antioxidants","confidence":"Medium","confidence_rationale":"Tier 2–3 — direct physical interaction and enzymatic protection demonstrated, multiple Prx isoforms tested","pmids":["33669370"],"is_preprint":false},{"year":1999,"finding":"PTEN overexpression in glioblastoma cells blocks G0/G1 to S phase progression by recruiting the CDK inhibitor p27Kip1 into cyclin E/CDK2 complexes, resulting in reduced CDK2 kinase activity and decreased phosphorylated retinoblastoma protein; CDK4 activity and p21Cip1 levels are unaffected.","method":"Adenoviral gene transfer, cell cycle analysis, CDK2 kinase assay, co-immunoprecipitation of p27Kip1 with cyclin E","journal":"Cancer research","confidence":"Medium","confidence_rationale":"Tier 2 — cell cycle analysis with CDK kinase assay and co-IP demonstrating mechanism of G1 arrest","pmids":["10344736"],"is_preprint":false},{"year":2000,"finding":"PTEN expression in glioma cells inhibits phospholipase C signaling (reducing intracellular IP3 and extracellular Ca2+ influx) and inhibits integrin-linked kinase (ILK) activity through its catalytic activity; AKT3 (highly expressed in brain) is identified as a target for PTEN repression.","method":"IP3 measurement, Ca2+ influx assay, ILK activity assay, PTEN overexpression, catalytic mutant control","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 — multiple downstream pathway assays with catalytic mutant controls","pmids":["10644997"],"is_preprint":false}],"current_model":"PTEN is a dual-specificity lipid and protein phosphatase that primarily dephosphorylates PtdIns(3,4,5)P3 at the 3-position to antagonize PI3K/AKT signaling, while also directly dephosphorylating protein substrates including FAK, PGK1, and PLK1; its activity is regulated by C-terminal tail phosphorylation (autoinhibition via prevention of membrane association), reversible oxidation of the Cys124/Cys71 active site disulfide, and multiple post-translational modifications including acetylation (by PCAF at Lys125/128), poly-ADP-ribosylation (by tankyrases targeting it for RNF146-mediated ubiquitination and degradation), deubiquitylation (by USP13 for stabilization), S-nitrosylation (downstream of eNOS/AMPK), and compartment-specific ubiquitylation (nuclear PTEN at Lys221 by FBXO22); in the nucleus, PTEN associates with centromeres via CENP-C to maintain chromosomal stability, promotes RPA1 stability at replication forks, and stabilizes TOP2A for DNA decatenation, while cytoplasmic PTEN suppresses cell migration through FAK dephosphorylation, inhibits glycolysis through PGK1 dephosphorylation, and is transcriptionally induced by p53; pathway homeostasis is further maintained by mTOR/4E-BP1-dependent translational upregulation of PTEN upon PI3K activation."},"narrative":{"teleology":[{"year":1997,"claim":"Positional cloning at 10q23 identified PTEN as a candidate tumor suppressor with a protein phosphatase domain, resolving the identity of a frequently deleted locus in diverse cancers and establishing a phosphatase-based tumor suppression paradigm.","evidence":"Homozygous deletion mapping and mutation screening in cancer cell lines by two independent groups","pmids":["9072974","9090379","9187108"],"confidence":"High","gaps":["Physiological substrates unknown","Lipid phosphatase activity not yet recognized","In vivo tumor suppressor function not formally tested"]},{"year":1997,"claim":"Discovery that germline PTEN mutations cause Cowden disease established PTEN as a bona fide hereditary tumor suppressor, linking its phosphatase domain to human cancer predisposition.","evidence":"Germline mutational analysis of multiple Cowden disease kindreds","pmids":["9140396"],"confidence":"High","gaps":["Genotype–phenotype correlations for specific mutations unresolved","Whether protein or lipid phosphatase activity is critical for tumor suppression unknown"]},{"year":1998,"claim":"Identification of PIP3 as the primary physiological substrate of PTEN, with D3-specific dephosphorylation, transformed understanding from a protein phosphatase to a lipid phosphatase that directly antagonizes PI3K signaling and controls AKT activation.","evidence":"In vitro phosphatase assay with purified recombinant PTEN, active-site C124S mutagenesis, cellular PIP3 measurement; Cowden mutation G129E selectively ablating lipid but not protein phosphatase activity","pmids":["9593664","9811831"],"confidence":"High","gaps":["Structural basis for PIP3 recognition unresolved","Relative contribution of protein vs. lipid phosphatase activity to each tumor suppressor function unclear"]},{"year":1998,"claim":"Demonstration that PTEN suppresses cell migration by dephosphorylating FAK and inhibiting focal adhesion formation revealed a protein phosphatase-dependent function distinct from lipid phosphatase activity, establishing PTEN as a dual-function enzyme.","evidence":"Cell migration and focal adhesion assays, co-immunoprecipitation with FAK, phosphatase-dead mutant controls","pmids":["9616126"],"confidence":"High","gaps":["Whether FAK dephosphorylation occurs in vivo at physiological PTEN levels not established","Relative importance of FAK vs. PIP3 regulation for tumor suppression unclear"]},{"year":1998,"claim":"Pten knockout mice confirmed essential developmental and tumor-suppressive roles in vivo, with embryonic lethality in homozygotes and spontaneous tumors in heterozygotes, validating the haploinsufficient tumor suppressor model.","evidence":"Homologous recombination knockout in mice, histopathology, tumor spectrum analysis","pmids":["9697695"],"confidence":"High","gaps":["Tissue-specific contributions of PTEN loss not dissected","Nuclear vs. cytoplasmic functions not distinguished in vivo"]},{"year":1999,"claim":"The crystal structure revealed an enlarged active-site pocket accommodating PIP3 and a C2 domain mediating membrane recruitment, providing the structural basis for substrate specificity and explaining how cancer-associated mutations impair function.","evidence":"X-ray crystallography, lipid binding assay, C2 domain mutagenesis, cell growth suppression assay","pmids":["10555148"],"confidence":"High","gaps":["Full-length PTEN structure including C-terminal tail not resolved","Membrane-bound catalytic conformation unknown"]},{"year":2001,"claim":"Identification of p53 as a direct transcriptional activator of PTEN, with PTEN required for p53-mediated apoptosis, established a tumor suppressor signaling axis linking the two most frequently inactivated genes in cancer.","evidence":"PTEN promoter deletion and mutation analysis, p53 induction, apoptosis in PTEN-null MEFs","pmids":["11545734"],"confidence":"High","gaps":["Whether p53-PTEN axis operates equivalently in all tissue contexts unknown","Post-translational crosstalk beyond transcription not addressed"]},{"year":2002,"claim":"Discovery of reversible oxidative inactivation through a Cys124–Cys71 disulfide bond, reactivated by thioredoxin, revealed that ROS directly regulate PTEN and link redox signaling to PI3K pathway activation.","evidence":"Purified PTEN oxidation, mass spectrometry of disulfide, cysteine mutant analysis, co-IP with thioredoxin, cell-based inhibitor studies","pmids":["11916965"],"confidence":"High","gaps":["Quantitative contribution of oxidative inactivation to PTEN regulation in specific tissues unknown","Role of other reductases in vivo not fully excluded"]},{"year":2006,"claim":"Identification of PCAF-mediated acetylation at Lys125/128 within the catalytic cleft as an inhibitory modification demonstrated a growth-factor-responsive epigenetic switch that tunes PTEN activity independently of protein levels.","evidence":"Co-IP, acetylation assay, PCAF shRNA, acetylation-resistant K125R/K128R mutagenesis, PI3K signaling and cell cycle analysis","pmids":["16829519"],"confidence":"High","gaps":["Identity of the deacetylase that reverses this modification not established","In vivo significance in tumorigenesis not tested"]},{"year":2007,"claim":"Nuclear PTEN was shown to associate with centromeres through CENP-C and maintain chromosomal stability independently of lipid phosphatase activity, establishing a phosphatase-independent genome guardian role.","evidence":"Co-immunoprecipitation of PTEN with CENP-C, immunofluorescence at centromeres, chromosome breakage analysis in Pten-null cells","pmids":["17218262"],"confidence":"High","gaps":["Whether CENP-C interaction is direct or bridged unknown","Mechanism by which PTEN at centromeres prevents breakage not molecularly defined"]},{"year":2013,"claim":"Identification of USP13 as a PTEN-stabilizing deubiquitinase established that PTEN protein levels are actively maintained by deubiquitylation, providing a mechanism for PTEN downregulation in cancers without genomic loss.","evidence":"Systematic DUB screen, direct binding by co-IP, ubiquitylation assay, tumor suppression only in PTEN-positive cells","pmids":["24270891"],"confidence":"High","gaps":["Which E3 ligase ubiquitylates PTEN in this context not identified","Tissue specificity of USP13-PTEN axis not resolved"]},{"year":2014,"claim":"Discovery that tankyrases PARylate PTEN to promote RNF146-mediated ubiquitination and degradation revealed a PARP-dependent proteolytic mechanism for PTEN turnover, connecting poly-ADP-ribosylation to PI3K/AKT signaling control.","evidence":"Co-IP, ADP-ribosylation assay, ubiquitination assay, tankyrase knockdown, AKT signaling, in vivo tumor model","pmids":["25547115"],"confidence":"High","gaps":["Specific PARylation sites on PTEN not mapped","Interplay between tankyrase-mediated degradation and USP13-mediated stabilization not quantified"]},{"year":2015,"claim":"PTEN was shown to localize at replication forks, stabilize RPA1 through OTUB1-mediated deubiquitination, and maintain fork integrity under replication stress, extending its genome-protective role to DNA replication.","evidence":"iPOND, STORM super-resolution imaging, co-IP with RPA1, deubiquitylation assay, hydroxyurea-induced replication stress","pmids":["26403191"],"confidence":"High","gaps":["Whether PTEN phosphatase activity is required for replication fork protection unclear","How PTEN is recruited to forks not defined"]},{"year":2017,"claim":"PTEN S-nitrosylation downstream of AMPK-activated eNOS was identified as a mechanism linking metabolic/energy stress to PTEN inactivation and subsequent PI3K pathway activation, mediated by PARK2 deficiency.","evidence":"S-nitrosylation assay, AMPK activation, eNOS inhibition, ubiquitination assay, genetic validation in Park2/Pten compound mouse model","pmids":["28306514"],"confidence":"High","gaps":["Specific cysteine residue(s) targeted by S-nitrosylation not fully resolved","Whether this mechanism operates outside Parkinson's-related contexts not established"]},{"year":2019,"claim":"Direct dephosphorylation of PGK1 at Y324 by PTEN's protein phosphatase activity was shown to suppress glycolysis and brain tumorigenesis, establishing a metabolic tumor suppressor function distinct from PIP3 regulation.","evidence":"In vitro phosphatase assay, co-IP, glycolysis measurement, PGK1-Y324F knockin mouse, human GBM specimen analysis","pmids":["31492635"],"confidence":"High","gaps":["Whether PGK1 dephosphorylation contributes to tumor suppression outside brain not tested","Full scope of PTEN protein substrates in metabolism not surveyed"]},{"year":2020,"claim":"FBXO22 was identified as a compartment-specific E3 ligase that ubiquitylates nuclear PTEN at Lys221 for proteasomal degradation, resolving how nuclear and cytoplasmic PTEN pools are differentially regulated.","evidence":"Co-IP, ubiquitylation assay, K221 mutagenesis, nuclear/cytoplasmic fractionation, functional tumor assays","pmids":["32249768"],"confidence":"High","gaps":["Signals that trigger FBXO22-mediated nuclear PTEN degradation not defined","Interplay with monoubiquitylation-dependent nuclear import unclear"]},{"year":2021,"claim":"A homeostatic feedback loop was identified in which PI3K activation increases PTEN translation through mTOR/4E-BP1, explaining pathway self-limitation and rebound signaling upon PI3K inhibitor withdrawal.","evidence":"4E-BP1 genetic deletion, translational rate measurement, pharmacologic PI3K inhibition, in vitro and in vivo signaling assays","pmids":["33606974"],"confidence":"High","gaps":["Whether other translational regulators cooperate with 4E-BP1 for PTEN mRNA not tested","Clinical implications for PI3K inhibitor resistance not mechanistically validated"]},{"year":null,"claim":"Key unresolved questions include the full-length membrane-engaged PTEN structure, the complete inventory of direct protein substrates, the quantitative interplay among competing PTMs (phosphorylation, ubiquitylation, acetylation, PARylation, S-nitrosylation, oxidation) in specific tissue and signaling contexts, and how nuclear versus cytoplasmic PTEN pools are coordinately regulated to balance genome integrity and PI3K signaling functions.","evidence":"","pmids":[],"confidence":"Medium","gaps":["Full-length PTEN structure with C-terminal tail and membrane not resolved","Systematic identification of protein phosphatase substrates incomplete","Quantitative modeling of competing PTM inputs not achieved"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[2,6,9,26,28]},{"term_id":"GO:0016787","term_label":"hydrolase activity","supporting_discovery_ids":[4,5,8]},{"term_id":"GO:0008289","term_label":"lipid binding","supporting_discovery_ids":[4,5,8]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[4,5,11,32]}],"localization":[{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[2,17,31]},{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[16,19,30]},{"term_id":"GO:0005694","term_label":"chromosome","supporting_discovery_ids":[16]},{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[8,18,31]},{"term_id":"GO:0005739","term_label":"mitochondrion","supporting_discovery_ids":[24]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[4,5,11,32,35]},{"term_id":"R-HSA-1640170","term_label":"Cell Cycle","supporting_discovery_ids":[26,34]},{"term_id":"R-HSA-5357801","term_label":"Programmed Cell Death","supporting_discovery_ids":[11,12]},{"term_id":"R-HSA-73894","term_label":"DNA Repair","supporting_discovery_ids":[16,23]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[0,1,3,7]},{"term_id":"R-HSA-392499","term_label":"Metabolism of proteins","supporting_discovery_ids":[21,22,30]},{"term_id":"R-HSA-1430728","term_label":"Metabolism","supporting_discovery_ids":[28]}],"complexes":["PTEN-associated complex (PAC, >600 kDa)"],"partners":["FAK","CENP-C","RPA1","TOP2A","PLK1","PGK1","USP13","PCAF"],"other_free_text":[]},"mechanistic_narrative":"PTEN is a dual-specificity phosphatase that functions as a major tumor suppressor by dephosphorylating phosphatidylinositol 3,4,5-trisphosphate (PIP3) at the D3 position, thereby antagonizing PI3K/AKT signaling to control cell survival, proliferation, and metabolism [PMID:9593664, PMID:9811831]. Beyond its lipid phosphatase activity, PTEN directly dephosphorylates protein substrates including FAK (suppressing cell migration), PGK1 (inhibiting glycolysis), and PLK1 (preventing polyploidy), and it maintains genomic integrity through nuclear functions that include centromere association via CENP-C, stabilization of RPA1 at replication forks, and promotion of TOP2A-dependent DNA decatenation [PMID:9616126, PMID:31492635, PMID:17218262, PMID:26403191, PMID:26657567]. PTEN activity is regulated by C-terminal tail phosphorylation-dependent autoinhibition, reversible oxidative inactivation through a Cys124–Cys71 disulfide, acetylation at Lys125/128 by PCAF, S-nitrosylation downstream of AMPK/eNOS, tankyrase-mediated PARylation leading to RNF146-dependent degradation, stabilization by the deubiquitinase USP13, and compartment-specific nuclear degradation by the E3 ligase FBXO22 at Lys221 [PMID:18794881, PMID:11916965, PMID:16829519, PMID:28306514, PMID:25547115, PMID:24270891, PMID:32249768]. Germline PTEN mutations cause Cowden disease, a cancer predisposition syndrome [PMID:9140396]."},"prefetch_data":{"uniprot":{"accession":"P60484","full_name":"Phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN","aliases":["Inositol polyphosphate 3-phosphatase","Mutated in multiple advanced cancers 1","Phosphatase and tensin homolog"],"length_aa":403,"mass_kda":47.2,"function":"Dual-specificity protein phosphatase, dephosphorylating tyrosine-, serine- and threonine-phosphorylated proteins (PubMed:9187108, PubMed:9256433, PubMed:9616126). Also functions as a lipid phosphatase, removing the phosphate in the D3 position of the inositol ring of PtdIns(3,4,5)P3/phosphatidylinositol 3,4,5-trisphosphate, PtdIns(3,4)P2/phosphatidylinositol 3,4-diphosphate and PtdIns3P/phosphatidylinositol 3-phosphate with a preference for PtdIns(3,4,5)P3 (PubMed:16824732, PubMed:26504226, PubMed:9593664, PubMed:9811831). Furthermore, this enzyme can also act as a cytosolic inositol 3-phosphatase acting on Ins(1,3,4,5,6)P5/inositol 1,3,4,5,6 pentakisphosphate and possibly Ins(1,3,4,5)P4/1D-myo-inositol 1,3,4,5-tetrakisphosphate (PubMed:11418101, PubMed:15979280). Antagonizes the PI3K-AKT/PKB signaling pathway by dephosphorylating phosphoinositides and thereby modulating cell cycle progression and cell survival (PubMed:31492966, PubMed:37279284). The unphosphorylated form cooperates with MAGI2 to suppress AKT1 activation (PubMed:11707428). In motile cells, suppresses the formation of lateral pseudopods and thereby promotes cell polarization and directed movement (PubMed:22279049). Dephosphorylates tyrosine-phosphorylated focal adhesion kinase and inhibits cell migration and integrin-mediated cell spreading and focal adhesion formation (PubMed:22279049). Required for growth factor-induced epithelial cell migration; growth factor stimulation induces PTEN phosphorylation which changes its binding preference from the p85 regulatory subunit of the PI3K kinase complex to DLC1 and results in translocation of the PTEN-DLC1 complex to the posterior of migrating cells to promote RHOA activation (PubMed:26166433). Meanwhile, TNS3 switches binding preference from DLC1 to p85 and the TNS3-p85 complex translocates to the leading edge of migrating cells to activate RAC1 activation (PubMed:26166433). Plays a role as a key modulator of the AKT-mTOR signaling pathway controlling the tempo of the process of newborn neurons integration during adult neurogenesis, including correct neuron positioning, dendritic development and synapse formation (By similarity). Involved in the regulation of synaptic function in excitatory hippocampal synapses. Recruited to the postsynaptic membrane upon NMDA receptor activation, is required for the modulation of synaptic activity during plasticity. Enhancement of lipid phosphatase activity is able to drive depression of AMPA receptor-mediated synaptic responses, activity required for NMDA receptor-dependent long-term depression (LTD) (By similarity). May be a negative regulator of insulin signaling and glucose metabolism in adipose tissue. The nuclear monoubiquitinated form possesses greater apoptotic potential, whereas the cytoplasmic nonubiquitinated form induces less tumor suppressive ability (PubMed:10468583, PubMed:18716620) Functional kinase, like isoform 1 it antagonizes the PI3K-AKT/PKB signaling pathway. Plays a role in mitochondrial energetic metabolism by promoting COX activity and ATP production, via collaboration with isoform 1 in increasing protein levels of PINK1","subcellular_location":"Secreted","url":"https://www.uniprot.org/uniprotkb/P60484/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/PTEN","classification":"Not Classified","n_dependent_lines":17,"n_total_lines":1208,"dependency_fraction":0.014072847682119206},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/PTEN","total_profiled":1310},"omim":[{"mim_id":"621247","title":"CLEAVAGE AND POLYADENYLATION SPECIFICITY FACTOR 7; CPSF7","url":"https://www.omim.org/entry/621247"},{"mim_id":"621007","title":"ZINC FINGER PROTEIN 800; ZNF800","url":"https://www.omim.org/entry/621007"},{"mim_id":"620760","title":"MITOCHONDRIAL LACTATE DEHYDROGENASE REGULATOR; MLDHR","url":"https://www.omim.org/entry/620760"},{"mim_id":"618909","title":"ILK-ASSOCIATED SERINE/THREONINE PHOSPHATASE; ILKAP","url":"https://www.omim.org/entry/618909"},{"mim_id":"618303","title":"CAVEOLAE-ASSOCIATED PROTEIN 3; CAVIN3","url":"https://www.omim.org/entry/618303"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Nucleoplasm","reliability":"Supported"},{"location":"Cytosol","reliability":"Supported"},{"location":"Mid piece","reliability":"Additional"},{"location":"Principal piece","reliability":"Additional"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/PTEN"},"hgnc":{"alias_symbol":["MMAC1","TEP1","PTEN1"],"prev_symbol":["BZS","MHAM"]},"alphafold":{"accession":"P60484","domains":[{"cath_id":"3.90.190.10","chopping":"1-187","consensus_level":"medium","plddt":93.8022,"start":1,"end":187},{"cath_id":"2.60.40.1110","chopping":"191-283_302-348","consensus_level":"high","plddt":92.1627,"start":191,"end":348}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P60484","model_url":"https://alphafold.ebi.ac.uk/files/AF-P60484-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P60484-F1-predicted_aligned_error_v6.png","plddt_mean":83.0},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=PTEN","jax_strain_url":"https://www.jax.org/strain/search?query=PTEN"},"sequence":{"accession":"P60484","fasta_url":"https://rest.uniprot.org/uniprotkb/P60484.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P60484/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P60484"}},"corpus_meta":[{"pmid":"9593664","id":"PMC_9593664","title":"The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate.","date":"1998","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/9593664","citation_count":2594,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9990064","id":"PMC_9990064","title":"Mutation of Pten/Mmac1 in mice causes neoplasia in multiple organ systems.","date":"1999","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/9990064","citation_count":805,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9187108","id":"PMC_9187108","title":"TEP1, encoded by a candidate tumor suppressor locus, is a novel protein tyrosine phosphatase regulated by transforming growth factor beta.","date":"1997","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/9187108","citation_count":791,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11545734","id":"PMC_11545734","title":"Regulation of PTEN transcription by p53.","date":"2001","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/11545734","citation_count":771,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9560261","id":"PMC_9560261","title":"Inactivation of the tumor suppressor PTEN/MMAC1 in advanced human prostate cancer through loss of expression.","date":"1998","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/9560261","citation_count":543,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24905788","id":"PMC_24905788","title":"PTEN.","date":"2014","source":"Annual review of biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/24905788","citation_count":478,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19595306","id":"PMC_19595306","title":"PI3K/PTEN signaling in angiogenesis and tumorigenesis.","date":"2009","source":"Advances in cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/19595306","citation_count":461,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10564676","id":"PMC_10564676","title":"Mutational spectra of PTEN/MMAC1 gene: a tumor suppressor with lipid phosphatase activity.","date":"1999","source":"Journal of the National Cancer Institute","url":"https://pubmed.ncbi.nlm.nih.gov/10564676","citation_count":415,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9259288","id":"PMC_9259288","title":"Germline mutations in the PTEN/MMAC1 gene in patients with Cowden disease.","date":"1997","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/9259288","citation_count":397,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9443392","id":"PMC_9443392","title":"Interfocal heterogeneity of PTEN/MMAC1 gene alterations in multiple metastatic prostate cancer tissues.","date":"1998","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/9443392","citation_count":374,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11875759","id":"PMC_11875759","title":"Protean PTEN: form and function.","date":"2002","source":"American journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/11875759","citation_count":349,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17341655","id":"PMC_17341655","title":"PTEN, more than the AKT pathway.","date":"2007","source":"Carcinogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/17341655","citation_count":338,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9619835","id":"PMC_9619835","title":"PTEN mutations in gliomas and glioneuronal tumors.","date":"1998","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/9619835","citation_count":295,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17964232","id":"PMC_17964232","title":"PI3K/PTEN signaling in tumorigenesis and angiogenesis.","date":"2007","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/17964232","citation_count":280,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10923032","id":"PMC_10923032","title":"Mutations of the human PTEN gene.","date":"2000","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/10923032","citation_count":266,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24656806","id":"PMC_24656806","title":"PTEN function: the long and the short of it.","date":"2014","source":"Trends in biochemical sciences","url":"https://pubmed.ncbi.nlm.nih.gov/24656806","citation_count":249,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18216329","id":"PMC_18216329","title":"The nuclear affairs of PTEN.","date":"2008","source":"Journal of cell science","url":"https://pubmed.ncbi.nlm.nih.gov/18216329","citation_count":242,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30999672","id":"PMC_30999672","title":"The PTEN⁻PI3K Axis in Cancer.","date":"2019","source":"Biomolecules","url":"https://pubmed.ncbi.nlm.nih.gov/30999672","citation_count":234,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11896207","id":"PMC_11896207","title":"Promoter methylation and silencing of PTEN in gastric carcinoma.","date":"2002","source":"Laboratory investigation; a journal of technical methods and pathology","url":"https://pubmed.ncbi.nlm.nih.gov/11896207","citation_count":216,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20622047","id":"PMC_20622047","title":"PI(3)king apart PTEN's role in cancer.","date":"2010","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/20622047","citation_count":205,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31433956","id":"PMC_31433956","title":"The Clinical Spectrum of PTEN Mutations.","date":"2019","source":"Annual review of medicine","url":"https://pubmed.ncbi.nlm.nih.gov/31433956","citation_count":204,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24387334","id":"PMC_24387334","title":"Therapeutic targeting of cancers with loss of PTEN function.","date":"2014","source":"Current drug targets","url":"https://pubmed.ncbi.nlm.nih.gov/24387334","citation_count":196,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18794877","id":"PMC_18794877","title":"PTEN signaling in brain: neuropathology and tumorigenesis.","date":"2008","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/18794877","citation_count":191,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15147864","id":"PMC_15147864","title":"Bisperoxovanadium compounds are potent PTEN inhibitors.","date":"2004","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/15147864","citation_count":191,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18794881","id":"PMC_18794881","title":"Understanding PTEN regulation: PIP2, polarity and protein stability.","date":"2008","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/18794881","citation_count":190,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16829519","id":"PMC_16829519","title":"PCAF modulates PTEN activity.","date":"2006","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/16829519","citation_count":188,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9622068","id":"PMC_9622068","title":"Suppression of tumorigenicity of glioblastoma cells by adenovirus-mediated MMAC1/PTEN gene transfer.","date":"1998","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/9622068","citation_count":185,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24270891","id":"PMC_24270891","title":"Deubiquitylation and stabilization of PTEN by USP13.","date":"2013","source":"Nature cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/24270891","citation_count":181,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31492635","id":"PMC_31492635","title":"PTEN Suppresses Glycolysis by Dephosphorylating and Inhibiting Autophosphorylated PGK1.","date":"2019","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/31492635","citation_count":175,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9393744","id":"PMC_9393744","title":"PTEN/MMAC1 mutations and EGFR amplification in glioblastomas.","date":"1997","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/9393744","citation_count":171,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16675164","id":"PMC_16675164","title":"Regulation of the PTEN phosphatase.","date":"2006","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/16675164","citation_count":162,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11495901","id":"PMC_11495901","title":"PTEN induces chemosensitivity in PTEN-mutated prostate cancer cells by suppression of Bcl-2 expression.","date":"2001","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11495901","citation_count":161,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9458098","id":"PMC_9458098","title":"Analysis of PTEN/MMAC1 alterations in aerodigestive tract tumors.","date":"1998","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/9458098","citation_count":144,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10646847","id":"PMC_10646847","title":"Threonine phosphorylation of the MMAC1/PTEN PDZ binding domain both inhibits and stimulates PDZ binding.","date":"2000","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/10646847","citation_count":141,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10551828","id":"PMC_10551828","title":"Vaults and telomerase share a common subunit, TEP1.","date":"1999","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/10551828","citation_count":133,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30311380","id":"PMC_30311380","title":"Gene-specific criteria for PTEN variant curation: Recommendations from the ClinGen PTEN Expert Panel.","date":"2018","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/30311380","citation_count":128,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31196157","id":"PMC_31196157","title":"PTENP1/miR-20a/PTEN axis contributes to breast cancer progression by regulating PTEN via PI3K/AKT pathway.","date":"2019","source":"Journal of experimental & clinical cancer research : CR","url":"https://pubmed.ncbi.nlm.nih.gov/31196157","citation_count":123,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26284192","id":"PMC_26284192","title":"Focus on PTEN Regulation.","date":"2015","source":"Frontiers in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/26284192","citation_count":122,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10469123","id":"PMC_10469123","title":"PTEN/MMAC1/TEP1 in signal transduction and tumorigenesis.","date":"1999","source":"European journal of biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/10469123","citation_count":118,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19057511","id":"PMC_19057511","title":"PTEN regulation by Akt-EGR1-ARF-PTEN axis.","date":"2008","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/19057511","citation_count":115,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25547115","id":"PMC_25547115","title":"Poly-ADP ribosylation of PTEN by tankyrases promotes PTEN degradation and tumor growth.","date":"2014","source":"Genes & development","url":"https://pubmed.ncbi.nlm.nih.gov/25547115","citation_count":115,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28306514","id":"PMC_28306514","title":"PARK2 Depletion Connects Energy and Oxidative Stress to PI3K/Akt Activation via PTEN S-Nitrosylation.","date":"2017","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/28306514","citation_count":113,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33606974","id":"PMC_33606974","title":"Regulation of PTEN translation by PI3K signaling maintains pathway homeostasis.","date":"2021","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/33606974","citation_count":108,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12904991","id":"PMC_12904991","title":"PTEN methylation and expression in glioblastomas.","date":"2003","source":"Acta neuropathologica","url":"https://pubmed.ncbi.nlm.nih.gov/12904991","citation_count":105,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23613428","id":"PMC_23613428","title":"When overgrowth bumps into cancer: the PTEN-opathies.","date":"2013","source":"American journal of medical genetics. Part C, Seminars in medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/23613428","citation_count":105,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17575145","id":"PMC_17575145","title":"Acquired resistance to erlotinib in A-431 epidermoid cancer cells requires down-regulation of MMAC1/PTEN and up-regulation of phosphorylated Akt.","date":"2007","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/17575145","citation_count":103,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12655146","id":"PMC_12655146","title":"Physiological functions of Pten in mouse tissues.","date":"2003","source":"Cell structure and function","url":"https://pubmed.ncbi.nlm.nih.gov/12655146","citation_count":92,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17972252","id":"PMC_17972252","title":"Why is PTEN an important tumor suppressor?","date":"2007","source":"Journal of cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/17972252","citation_count":92,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24062990","id":"PMC_24062990","title":"Genomic Rearrangements of PTEN in Prostate Cancer.","date":"2013","source":"Frontiers in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/24062990","citation_count":91,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9689095","id":"PMC_9689095","title":"In vitro loss of heterozygosity targets the PTEN/MMAC1 gene in melanoma.","date":"1998","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/9689095","citation_count":91,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15090541","id":"PMC_15090541","title":"PTEN regulates Mdm2 expression through the P1 promoter.","date":"2004","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/15090541","citation_count":84,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33166764","id":"PMC_33166764","title":"Regulatory role of microRNAs on PTEN signaling.","date":"2020","source":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","url":"https://pubmed.ncbi.nlm.nih.gov/33166764","citation_count":81,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28602818","id":"PMC_28602818","title":"Cell Cycle Control by PTEN.","date":"2017","source":"Journal of molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/28602818","citation_count":80,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19635806","id":"PMC_19635806","title":"p85 Associates with unphosphorylated PTEN and the PTEN-associated complex.","date":"2009","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/19635806","citation_count":80,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10344736","id":"PMC_10344736","title":"Adenovirus-mediated gene transfer of MMAC1/PTEN to glioblastoma cells inhibits S phase entry by the recruitment of p27Kip1 into cyclin E/CDK2 complexes.","date":"1999","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/10344736","citation_count":80,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32249768","id":"PMC_32249768","title":"FBXO22 degrades nuclear PTEN to promote tumorigenesis.","date":"2020","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/32249768","citation_count":79,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26403191","id":"PMC_26403191","title":"PTEN regulates RPA1 and protects DNA replication forks.","date":"2015","source":"Cell research","url":"https://pubmed.ncbi.nlm.nih.gov/26403191","citation_count":78,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9788441","id":"PMC_9788441","title":"PTEN/MMAC1 is infrequently mutated in pT2 and pT3 carcinomas of the prostate.","date":"1998","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/9788441","citation_count":77,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18201277","id":"PMC_18201277","title":"Portrait of PTEN: messages from mutant mice.","date":"2008","source":"Cancer science","url":"https://pubmed.ncbi.nlm.nih.gov/18201277","citation_count":76,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28289760","id":"PMC_28289760","title":"PTEN proteoforms in biology and disease.","date":"2017","source":"Cellular and molecular life sciences : CMLS","url":"https://pubmed.ncbi.nlm.nih.gov/28289760","citation_count":75,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11029039","id":"PMC_11029039","title":"Polymerization defects within human telomerase are distinct from telomerase RNA and TEP1 binding.","date":"2000","source":"Molecular biology of the cell","url":"https://pubmed.ncbi.nlm.nih.gov/11029039","citation_count":74,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28677502","id":"PMC_28677502","title":"PTEN, Insulin Resistance and Cancer.","date":"2017","source":"Current pharmaceutical design","url":"https://pubmed.ncbi.nlm.nih.gov/28677502","citation_count":73,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11027287","id":"PMC_11027287","title":"Telomerase-associated protein TEP1 is not essential for telomerase activity or telomere length maintenance in vivo.","date":"2000","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/11027287","citation_count":72,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9484844","id":"PMC_9484844","title":"PTEN/MMAC1 mutations in primary glioblastomas and short-term cultures of malignant gliomas.","date":"1998","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/9484844","citation_count":69,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16495927","id":"PMC_16495927","title":"Tumours and tremors: how PTEN regulation underlies both.","date":"2006","source":"British journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/16495927","citation_count":69,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20872961","id":"PMC_20872961","title":"PTEN in liver diseases and cancer.","date":"2010","source":"World journal of gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/20872961","citation_count":65,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30217221","id":"PMC_30217221","title":"Regulation of PTEN expression by noncoding RNAs.","date":"2018","source":"Journal of experimental & clinical cancer research : CR","url":"https://pubmed.ncbi.nlm.nih.gov/30217221","citation_count":65,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18759931","id":"PMC_18759931","title":"Regulation of T-cell responses by PTEN.","date":"2008","source":"Immunological reviews","url":"https://pubmed.ncbi.nlm.nih.gov/18759931","citation_count":64,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31636093","id":"PMC_31636093","title":"Structural Mechanisms of PTEN Regulation.","date":"2020","source":"Cold Spring Harbor perspectives in medicine","url":"https://pubmed.ncbi.nlm.nih.gov/31636093","citation_count":63,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30145641","id":"PMC_30145641","title":"Regulation and modulation of PTEN activity.","date":"2018","source":"Molecular biology reports","url":"https://pubmed.ncbi.nlm.nih.gov/30145641","citation_count":61,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10706759","id":"PMC_10706759","title":"Mutation analysis of PTEN/MMAC1 in acute myeloid leukemia.","date":"2000","source":"American journal of hematology","url":"https://pubmed.ncbi.nlm.nih.gov/10706759","citation_count":60,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11297763","id":"PMC_11297763","title":"PTEN/MMAC1 in malignant melanoma and its importance for tumor progression.","date":"2001","source":"Cancer genetics and cytogenetics","url":"https://pubmed.ncbi.nlm.nih.gov/11297763","citation_count":60,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32399470","id":"PMC_32399470","title":"The Role of PTEN in Neurodevelopment.","date":"2020","source":"Molecular neuropsychiatry","url":"https://pubmed.ncbi.nlm.nih.gov/32399470","citation_count":59,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25312582","id":"PMC_25312582","title":"Study of PTEN subcellular localization.","date":"2014","source":"Methods (San Diego, Calif.)","url":"https://pubmed.ncbi.nlm.nih.gov/25312582","citation_count":59,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10966170","id":"PMC_10966170","title":"Mutational analysis of the tumour suppressor gene MMAC1/PTEN in malignant myeloid disorders.","date":"2000","source":"European journal of haematology","url":"https://pubmed.ncbi.nlm.nih.gov/10966170","citation_count":59,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25336918","id":"PMC_25336918","title":"Posttranslational regulation of phosphatase and tensin homolog (PTEN) and its functional impact on cancer behaviors.","date":"2014","source":"Drug design, development and therapy","url":"https://pubmed.ncbi.nlm.nih.gov/25336918","citation_count":58,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17827710","id":"PMC_17827710","title":"PTEN: its deregulation and tumorigenesis.","date":"2007","source":"Biological & pharmaceutical bulletin","url":"https://pubmed.ncbi.nlm.nih.gov/17827710","citation_count":58,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33105713","id":"PMC_33105713","title":"The PTEN Conundrum: How to Target PTEN-Deficient Prostate Cancer.","date":"2020","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/33105713","citation_count":56,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31569439","id":"PMC_31569439","title":"PTEN and Gynecological Cancers.","date":"2019","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/31569439","citation_count":54,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25012124","id":"PMC_25012124","title":"A serine protease homolog negatively regulates TEP1 consumption in systemic infections of the malaria vector Anopheles gambiae.","date":"2014","source":"Journal of innate immunity","url":"https://pubmed.ncbi.nlm.nih.gov/25012124","citation_count":51,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31570378","id":"PMC_31570378","title":"PTEN in Hereditary and Sporadic Cancer.","date":"2020","source":"Cold Spring Harbor perspectives in medicine","url":"https://pubmed.ncbi.nlm.nih.gov/31570378","citation_count":49,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33669370","id":"PMC_33669370","title":"Redox Regulation of PTEN by Peroxiredoxins.","date":"2021","source":"Antioxidants (Basel, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/33669370","citation_count":49,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28095489","id":"PMC_28095489","title":"Transgenic Expression of the Anti-parasitic Factor TEP1 in the Malaria Mosquito Anopheles gambiae.","date":"2017","source":"PLoS pathogens","url":"https://pubmed.ncbi.nlm.nih.gov/28095489","citation_count":48,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9697884","id":"PMC_9697884","title":"Mutational analysis of the PTEN/MMAC1 gene in non-Hodgkin's lymphoma.","date":"1998","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/9697884","citation_count":47,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24933481","id":"PMC_24933481","title":"NOTCH and PTEN in prostate cancer.","date":"2014","source":"Advances in biological regulation","url":"https://pubmed.ncbi.nlm.nih.gov/24933481","citation_count":43,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10644997","id":"PMC_10644997","title":"The MMAC1 tumor suppressor phosphatase inhibits phospholipase C and integrin-linked kinase activity.","date":"2000","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/10644997","citation_count":43,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31712221","id":"PMC_31712221","title":"PTEN Nuclear Functions.","date":"2020","source":"Cold Spring Harbor perspectives in medicine","url":"https://pubmed.ncbi.nlm.nih.gov/31712221","citation_count":42,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9797362","id":"PMC_9797362","title":"Mutational abrogation of the PTEN/MMAC1 gene in gastrointestinal polyps in patients with Cowden disease.","date":"1998","source":"Gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/9797362","citation_count":42,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26415504","id":"PMC_26415504","title":"AIF inhibits tumor metastasis by protecting PTEN from oxidation.","date":"2015","source":"EMBO reports","url":"https://pubmed.ncbi.nlm.nih.gov/26415504","citation_count":42,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9510470","id":"PMC_9510470","title":"Infrequent mutations in the PTEN/MMAC1 gene among primary breast cancers.","date":"1998","source":"Japanese journal of cancer research : Gann","url":"https://pubmed.ncbi.nlm.nih.gov/9510470","citation_count":41,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18059158","id":"PMC_18059158","title":"BMP suppresses PTEN expression via RAS/ERK signaling.","date":"2007","source":"Cancer biology & therapy","url":"https://pubmed.ncbi.nlm.nih.gov/18059158","citation_count":41,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25361917","id":"PMC_25361917","title":"Molecular pathways: intercellular PTEN and the potential of PTEN restoration therapy.","date":"2014","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/25361917","citation_count":40,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11234884","id":"PMC_11234884","title":"Mutations of PTEN/MMAC1 in primary prostate cancers from Chinese patients.","date":"2001","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/11234884","citation_count":40,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18840262","id":"PMC_18840262","title":"The evolution of TEP1, an exceptionally polymorphic immunity gene in Anopheles gambiae.","date":"2008","source":"BMC evolutionary biology","url":"https://pubmed.ncbi.nlm.nih.gov/18840262","citation_count":40,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26657567","id":"PMC_26657567","title":"PTEN stabilizes TOP2A and regulates the DNA decatenation.","date":"2015","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/26657567","citation_count":39,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31551414","id":"PMC_31551414","title":"Identification of the PTEN-ARID4B-PI3K pathway reveals the dependency on ARID4B by PTEN-deficient prostate cancer.","date":"2019","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/31551414","citation_count":39,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31932468","id":"PMC_31932468","title":"Posttranslational Regulation and Conformational Plasticity of PTEN.","date":"2020","source":"Cold Spring Harbor perspectives in medicine","url":"https://pubmed.ncbi.nlm.nih.gov/31932468","citation_count":37,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31530116","id":"PMC_31530116","title":"An update on PTEN modulators - a patent review.","date":"2019","source":"Expert opinion on therapeutic patents","url":"https://pubmed.ncbi.nlm.nih.gov/31530116","citation_count":36,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9600246","id":"PMC_9600246","title":"The genetic basis of Cowden's syndrome: three novel mutations in PTEN/MMAC1/TEP1.","date":"1998","source":"Human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/9600246","citation_count":35,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27398835","id":"PMC_27398835","title":"PTEN regulates PLK1 and controls chromosomal stability during cell division.","date":"2016","source":"Cell cycle (Georgetown, Tex.)","url":"https://pubmed.ncbi.nlm.nih.gov/27398835","citation_count":35,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9072974","id":"PMC_9072974","title":"PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer.","date":"1997","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/9072974","citation_count":4169,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"9090379","id":"PMC_9090379","title":"Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers.","date":"1997","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/9090379","citation_count":2442,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"17681183","id":"PMC_17681183","title":"MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer.","date":"2007","source":"Gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/17681183","citation_count":2291,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"23788249","id":"PMC_23788249","title":"ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing.","date":"2013","source":"Genetics in medicine : official journal of the American College of Medical Genetics","url":"https://pubmed.ncbi.nlm.nih.gov/23788249","citation_count":1945,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"16169070","id":"PMC_16169070","title":"A human protein-protein interaction network: a resource for annotating the proteome.","date":"2005","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/16169070","citation_count":1704,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"9140396","id":"PMC_9140396","title":"Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome.","date":"1997","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/9140396","citation_count":1644,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"22473468","id":"PMC_22473468","title":"The functions and regulation of the PTEN tumour suppressor.","date":"2012","source":"Nature reviews. Molecular cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/22473468","citation_count":1642,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12477932","id":"PMC_12477932","title":"Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences.","date":"2002","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/12477932","citation_count":1479,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"21252315","id":"PMC_21252315","title":"DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors.","date":"2011","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/21252315","citation_count":1392,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"17936563","id":"PMC_17936563","title":"A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer.","date":"2007","source":"Cancer cell","url":"https://pubmed.ncbi.nlm.nih.gov/17936563","citation_count":1328,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"9697695","id":"PMC_9697695","title":"Pten is essential for embryonic development and tumour suppression.","date":"1998","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/9697695","citation_count":1280,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"26645196","id":"PMC_26645196","title":"Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy.","date":"2015","source":"Cancer discovery","url":"https://pubmed.ncbi.nlm.nih.gov/26645196","citation_count":1264,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"9616126","id":"PMC_9616126","title":"Inhibition of cell migration, spreading, and focal adhesions by tumor suppressor PTEN.","date":"1998","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/9616126","citation_count":1049,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"21575859","id":"PMC_21575859","title":"Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer.","date":"2011","source":"Cancer cell","url":"https://pubmed.ncbi.nlm.nih.gov/21575859","citation_count":1018,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"9811831","id":"PMC_9811831","title":"The lipid phosphatase activity of PTEN is critical for its tumor supressor function.","date":"1998","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/9811831","citation_count":1007,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"26479035","id":"PMC_26479035","title":"Microenvironment-induced PTEN loss by exosomal microRNA primes brain metastasis outgrowth.","date":"2015","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/26479035","citation_count":976,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"18199536","id":"PMC_18199536","title":"MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN.","date":"2008","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/18199536","citation_count":931,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"10555148","id":"PMC_10555148","title":"Crystal structure of the PTEN tumor suppressor: implications for its phosphoinositide phosphatase activity and membrane association.","date":"1999","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/10555148","citation_count":894,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"11916965","id":"PMC_11916965","title":"Reversible inactivation of the tumor suppressor PTEN by H2O2.","date":"2002","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11916965","citation_count":867,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"18676830","id":"PMC_18676830","title":"An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer.","date":"2008","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/18676830","citation_count":855,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"22000013","id":"PMC_22000013","title":"Coding-independent regulation of the tumor suppressor PTEN by competing endogenous mRNAs.","date":"2011","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/22000013","citation_count":842,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"24509480","id":"PMC_24509480","title":"Genome-wide trans-ancestry meta-analysis provides insight into the genetic architecture of type 2 diabetes susceptibility.","date":"2014","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/24509480","citation_count":834,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"16762633","id":"PMC_16762633","title":"Involvement of human micro-RNA in growth and response to chemotherapy in human cholangiocarcinoma cell lines.","date":"2006","source":"Gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/16762633","citation_count":816,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"17218262","id":"PMC_17218262","title":"Essential role for nuclear PTEN in maintaining chromosomal integrity.","date":"2007","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/17218262","citation_count":797,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"33229547","id":"PMC_33229547","title":"Oncogenic activation of PI3K-AKT-mTOR signaling suppresses ferroptosis via SREBP-mediated lipogenesis.","date":"2020","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/33229547","citation_count":792,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"16675393","id":"PMC_16675393","title":"Pten regulates neuronal arborization and social interaction in mice.","date":"2006","source":"Neuron","url":"https://pubmed.ncbi.nlm.nih.gov/16675393","citation_count":775,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"14702039","id":"PMC_14702039","title":"Complete sequencing and characterization of 21,243 full-length human cDNAs.","date":"2003","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/14702039","citation_count":754,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"17873882","id":"PMC_17873882","title":"Mutational loss of PTEN induces resistance to NOTCH1 inhibition in T-cell leukemia.","date":"2007","source":"Nature medicine","url":"https://pubmed.ncbi.nlm.nih.gov/17873882","citation_count":734,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"20797623","id":"PMC_20797623","title":"STAT3 activation of miR-21 and miR-181b-1 via PTEN and CYLD are part of the epigenetic switch linking inflammation to cancer.","date":"2010","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/20797623","citation_count":724,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"33961781","id":"PMC_33961781","title":"Dual proteome-scale networks reveal cell-specific remodeling of the human interactome.","date":"2021","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/33961781","citation_count":705,"is_preprint":false,"source_track":"gene2pubmed"}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":41702,"output_tokens":5865,"usd":0.10654},"stage2":{"model":"claude-opus-4-6","input_tokens":9440,"output_tokens":4468,"usd":0.23835},"total_usd":0.74395,"stage1_batch_id":"msgbatch_01SUR8NDzVrNmyszWyJeCct7","stage2_batch_id":"msgbatch_01G7Yfutko3cDWzejrwH5AMx","note":"batch pricing = 50% of standard","round2_stage1":{"model":"claude-sonnet-4-6","input_tokens":54255,"output_tokens":8327,"usd":0.143835},"round2_rules_fired":"R2,R3","round2_stage2":{"model":"claude-opus-4-6","input_tokens":12405,"output_tokens":4325,"usd":0.255225}},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1998,\n      \"finding\": \"PTEN dephosphorylates phosphatidylinositol 3,4,5-trisphosphate (PtdIns(3,4,5)P3) specifically at the 3-position of the inositol ring, acting as a lipid 3-phosphatase; the catalytically inactive C124S mutant cannot catalyze this reaction, confirming the phosphatase mechanism.\",\n      \"method\": \"In vitro phosphatase assay with purified recombinant PTEN; overexpression of wild-type and C124S mutant in 293 cells; measurement of PtdIns(3,4,5)P3 levels\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — reconstituted in vitro with purified protein, active-site mutagenesis, and cellular validation; foundational paper >2500 citations\",\n      \"pmids\": [\"9593664\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"PTEN (TEP1) possesses intrinsic protein tyrosine phosphatase activity and localizes to the cytoplasm, consistent with a role as a dual-specificity phosphatase.\",\n      \"method\": \"Cloning, biochemical phosphatase assay, immunofluorescence subcellular localization\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — enzymatic assay and direct localization experiment; single lab but orthogonal methods\",\n      \"pmids\": [\"9187108\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"p53 directly transactivates PTEN transcription through a p53 binding element upstream of the PTEN gene, and PTEN is required for p53-mediated apoptosis in mouse embryonic fibroblasts, placing PTEN downstream of p53 in the apoptotic pathway.\",\n      \"method\": \"Deletion and mutation analysis of PTEN promoter; p53 induction in primary and tumor cell lines; PTEN KO in MEFs with apoptosis readout\",\n      \"journal\": \"Molecular cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic epistasis with promoter dissection and loss-of-function phenotype; multiple orthogonal methods\",\n      \"pmids\": [\"11545734\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"The PTEN C-terminal PDZ binding domain interacts with hDLG and hMAST205 PDZ domains; threonine phosphorylation of this domain inhibits binding to hDLG/hMAST205 PDZ domains but promotes coprecipitation of ~90 and ~120 kDa proteins, revealing that phosphorylation of the PDZ binding domain bidirectionally regulates PTEN protein-protein interactions.\",\n      \"method\": \"Yeast two-hybrid, microtiter plate binding assay, peptide coprecipitation from A431 cell lysate, anti-hDLG antibody detection\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple binding assays with phospho-peptide competition; single lab\",\n      \"pmids\": [\"10646847\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"PCAF histone acetyltransferase physically interacts with PTEN and acetylates lysine residues K125 and K128 within the PTEN catalytic cleft in a growth factor-dependent manner; this acetylation inhibits PTEN's lipid phosphatase activity and PI3K/AKT suppression, and is required for PCAF-induced loss of G1 arrest.\",\n      \"method\": \"Co-immunoprecipitation, acetylation assay, shRNA knockdown of PCAF, acetylation-resistant PTEN mutants (K125R, K128R), cell cycle analysis\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — physical interaction demonstrated, mutagenesis of acetylation sites with functional validation of enzymatic activity and cell cycle arrest; multiple orthogonal methods\",\n      \"pmids\": [\"16829519\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"PTEN enters the nucleus by mechanisms including simple diffusion, active shuttling, cytoplasmic-localization-signal-dependent export, and monoubiquitylation-dependent import; nuclear PTEN plays roles in chromosome stability, DNA repair, and cell cycle arrest distinct from cytoplasmic PTEN.\",\n      \"method\": \"Review synthesizing direct localization and functional studies; monoubiquitylation-dependent nuclear import experiments\",\n      \"journal\": \"Journal of cell science\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — mechanistic localization studies summarized; some individual experiments on nuclear import mechanisms\",\n      \"pmids\": [\"18216329\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"USP13 is a deubiquitylase that directly binds and deubiquitylates PTEN, stabilizing the PTEN protein; loss of USP13 promotes AKT phosphorylation, cell proliferation, and tumor growth through PTEN downregulation.\",\n      \"method\": \"DUB screen (30 enzymes), Co-IP, deubiquitylation assay, USP13 knockdown with AKT phosphorylation and proliferation readouts, in vivo tumor growth assay\",\n      \"journal\": \"Nature cell biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — deubiquitylation assay, Co-IP, in vitro and in vivo functional validation; multiple orthogonal methods in single rigorous study\",\n      \"pmids\": [\"24270891\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Tankyrases (PARP family members) interact with and poly-ADP-ribosylate PTEN, which promotes recognition by the E3 ubiquitin ligase RNF146, leading to PTEN ubiquitination and degradation; tankyrase knockdown stabilizes PTEN and suppresses AKT phosphorylation.\",\n      \"method\": \"Co-IP, ADP-ribosylation assay, RNF146 interaction studies, tankyrase1/2 double knockdown with PTEN/AKT readouts, in vitro and in vivo tumor growth assays\",\n      \"journal\": \"Genes & development\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — novel PTM identified biochemically, E3 ligase substrate recognition mechanism established, in vivo validation; multiple orthogonal methods\",\n      \"pmids\": [\"25547115\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"PARK2 depletion activates AMPK-eNOS signaling, increasing nitric oxide and ROS levels, which promote S-nitrosylation of PTEN, inhibiting its function and activating PI3K/AKT; AMPK activation alone is sufficient to induce PTEN S-nitrosylation.\",\n      \"method\": \"PARK2 knockdown/KO, eNOS inhibition, ROS measurement, PTEN S-nitrosylation detection, AKT phosphorylation readouts, in vivo tumorigenesis with Park2/Pten compound mice\",\n      \"journal\": \"Molecular cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — mechanistic pathway established by epistasis, biochemical S-nitrosylation assay, in vivo cooperativity; multiple orthogonal methods\",\n      \"pmids\": [\"28306514\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"PTEN associates with p85 (the regulatory subunit of PI3K) and p110β within a >600 kDa PTEN-associated complex (PAC); this association involves the unphosphorylated form of PTEN and is enhanced by trastuzumab treatment, correlating with reduced AKT phosphorylation.\",\n      \"method\": \"Co-IP with new PTEN antibodies distinguishing phosphorylation state, gel filtration to identify PAC complex, trastuzumab treatment experiments\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal Co-IP with mechanistic detail on PTEN phosphorylation state; single lab but orthogonal methods\",\n      \"pmids\": [\"19635806\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"PTEN physically associates with replication protein A1 (RPA1) via the RPA1 C-terminal domain; PTEN localizes to replication sites (shown by STORM and iPOND) and recruits the deubiquitinase OTUB1 to mediate RPA1 deubiquitination, protecting replication forks from collapse under replication stress.\",\n      \"method\": \"Co-IP, STORM super-resolution microscopy, iPOND (isolation of proteins on nascent DNA), OTUB1 interaction, PTEN KO with fork stalling phenotype by hydroxyurea treatment\",\n      \"journal\": \"Cell research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — direct localization at replication forks by iPOND/STORM, physical interaction mapped, deubiquitination mechanism identified, KO phenotype; multiple orthogonal methods\",\n      \"pmids\": [\"26403191\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"PTEN physically associates with TOP2A (DNA topoisomerase IIα) and influences its stability through the OTUD3 deubiquitinase; PTEN deficiency leads to TOP2A downregulation, dysfunction of the decatenation checkpoint, and formation of ultra-fine bridges (UFBs) during anaphase.\",\n      \"method\": \"Co-IP, ubiquitination assay, PTEN KO with UFB detection by microscopy, OTUD3 interaction studies, decatenation checkpoint assay\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — physical interaction and deubiquitination mechanism shown, KO phenotype with defined readout; single lab\",\n      \"pmids\": [\"26657567\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"PTEN physically associates with PLK1 (polo-like kinase 1) and reduces PLK1 phosphorylation in a protein phosphatase-dependent manner; PTEN deficiency causes PLK1 hyperphosphorylation and polyploidy, which is rescued by inhibiting PLK1 or expressing a non-phosphorylatable PLK1 mutant.\",\n      \"method\": \"Co-IP, phosphatase assay, PTEN KO with chromosome content analysis, phospho-mimicking and non-phosphorylatable PLK1 mutants, PLK1 inhibitor rescue\",\n      \"journal\": \"Cell cycle (Georgetown, Tex.)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — substrate identification by Co-IP and phosphatase assay, genetic rescue with PLK1 mutants; single lab but multiple orthogonal methods\",\n      \"pmids\": [\"27398835\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"PTEN directly interacts with phosphoglycerate kinase 1 (PGK1) and uses its protein phosphatase activity to dephosphorylate PGK1 at autophosphorylated Y324, thereby inhibiting PGK1 enzymatic activity, glycolysis, ATP production, and brain tumor cell proliferation.\",\n      \"method\": \"Co-IP, in vitro protein phosphatase assay, PGK1 Y324F knockin mouse model, human GBM specimen analysis of PGK1 phosphorylation vs. PTEN status\",\n      \"journal\": \"Molecular cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — direct substrate dephosphorylation demonstrated in vitro, knockin mouse model validates in vivo relevance, human tissue correlation; rigorous multi-method study\",\n      \"pmids\": [\"31492635\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"PTEN transactivation by EGR1 requires p14ARF-mediated sumoylation of EGR1, which is dependent on Akt-mediated phosphorylation of EGR1 at S350 and T309; this defines an Akt-EGR1-ARF-PTEN feedback axis in which Akt activation feeds back to promote PTEN expression.\",\n      \"method\": \"In vivo sumoylation assay, Akt phosphorylation site mutants of EGR1, ARF-/- mouse analysis, PTEN promoter reporter assay\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — biochemical sumoylation and phosphorylation established, in vivo ARF-/- mouse validation; single lab but multiple methods\",\n      \"pmids\": [\"19057511\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"PTEN negatively regulates Mdm2 transcription at the P1 promoter through its lipid phosphatase activity (independent of p53), thereby controlling MDM2 isoform selection and blocking MDM2 nuclear translocation and protein destabilization.\",\n      \"method\": \"Pten-null cell lines and prostate cancer tissues, Mdm2 P1 promoter-reporter assay, lipid phosphatase-deficient PTEN mutant, immunoblot analysis\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — promoter assay with lipid phosphatase mutant controls, multiple cell systems; single lab\",\n      \"pmids\": [\"15090541\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Oncogenic and physiologic PI3K activation increase PTEN expression through mTOR/4E-BP1-dependent translational control; deletion of 4E-BP1 abolishes this translational upregulation, establishing mTOR-4E-BP1-dependent PTEN translation as a major homeostatic feedback mechanism.\",\n      \"method\": \"4E-BP1 deletion, mTOR inhibitor treatment, translational reporters, PI3K pathway modulation with pharmacologic and genetic tools\",\n      \"journal\": \"Molecular cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic deletion of 4E-BP1 with defined translational phenotype, pharmacologic and genetic orthogonal tools; strong mechanistic evidence\",\n      \"pmids\": [\"33606974\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"FBXO22 ubiquitylates nuclear PTEN specifically at lysine 221, targeting it for proteasomal degradation; nuclear PTEN is more unstable than cytoplasmic PTEN, and FBXO22-mediated degradation is specific to nuclear PTEN.\",\n      \"method\": \"Ubiquitylation assay, site-directed mutagenesis (K221), FBXO22 overexpression/knockdown, nuclear/cytoplasmic fractionation, colorectal cancer tissue analysis\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — ubiquitylation site mapped by mutagenesis, compartment-specific effect established by fractionation; single rigorous study with multiple orthogonal methods\",\n      \"pmids\": [\"32249768\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Apoptosis-inducing factor (AIF) physically interacts with PTEN and protects it from oxidation-mediated inactivation of its lipid phosphatase activity; AIF knockdown causes PTEN oxidation, AKT activation, β-catenin signaling, and promotes EMT and tumor metastasis.\",\n      \"method\": \"Co-IP, lipid phosphatase activity assay under oxidative conditions, AIF knockdown, in vitro and in vivo metastasis assays\",\n      \"journal\": \"EMBO reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct physical interaction and functional phosphatase assay, in vivo xenograft metastasis validation; single lab\",\n      \"pmids\": [\"26415504\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"PTEN overexpression in MMAC1-mutant glioblastoma cells induces G0/G1 cell cycle arrest by recruiting the CDK inhibitor p27Kip1 into cyclin E/CDK2 complexes, reducing CDK2 kinase activity and retinoblastoma protein phosphorylation, without affecting CDK4 activity.\",\n      \"method\": \"Adenoviral PTEN overexpression, flow cytometry, cyclin E immunoprecipitation/CDK2 kinase assay, p27Kip1 co-immunoprecipitation, pRb phosphorylation by Western blot\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — defined molecular mechanism of cell cycle arrest with kinase assay and substrate detection; single lab\",\n      \"pmids\": [\"10344736\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"PTEN (MMAC1) expression inhibits phospholipase C signaling (reducing inositol trisphosphate levels and extracellular Ca2+ influx) and inhibits integrin-linked kinase (ILK) activity in glioma cells; both effects require PTEN catalytic activity.\",\n      \"method\": \"MMAC1 expression in glioma cells, IP3 measurement, Ca2+ flux assay, ILK kinase assay, catalytic mutant controls\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — enzymatic readouts (IP3, Ca2+, ILK kinase) with catalytic mutant validation; single lab\",\n      \"pmids\": [\"10644997\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"PTEN inhibits the PI3K pathway by suppressing expression of ARID4B, a transcriptional activator of PI3K subunit genes PIK3CA and PIK3R2; ARID4B activates these promoters through displacement of histone H1 and chromatin remodeling, and ARID4B is required for prostate tumorigenesis when PTEN is deficient.\",\n      \"method\": \"PTEN KO with ARID4B expression analysis, chromatin immunoprecipitation of ARID4B and histone H1, PIK3CA/PIK3R2 promoter assay, ARID4B knockdown in PTEN-null tumors, in vivo tumorigenesis\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — pathway placed by genetic and ChIP evidence, in vivo validation; single lab\",\n      \"pmids\": [\"31551414\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"PTEN localizes to the endoplasmic reticulum (ER) and mitochondria-associated membranes (MAMs), where its protein phosphatase activity regulates inositol 1,4,5-trisphosphate receptor (IP3R)-mediated Ca2+ release from the ER and sensitivity to apoptosis.\",\n      \"method\": \"Subcellular fractionation, co-localization by fluorescence microscopy, IP3R interaction studies, Ca2+ flux measurement, PTEN KO apoptosis assay\",\n      \"journal\": \"Methods (San Diego, Calif.)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct subcellular localization tied to functional Ca2+ release mechanism; review but summarizes experimental findings\",\n      \"pmids\": [\"25312582\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"PTEN acts as an interfacial enzyme with high activity when transiently bound to membrane surfaces containing PtdIns(4,5)P2 and phosphatidylserine; oxidation of the active site cysteine by ROS and C-terminal serine/threonine phosphorylation inhibit PTEN activity, affect its stability and localization, and ubiquitination also regulates PTEN.\",\n      \"method\": \"Biochemical membrane binding assays, lipid phosphatase activity measurements under oxidizing conditions, phosphorylation-site mutant analysis\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple biochemical mechanistic insights on interfacial activity and redox regulation; synthesis of multiple experimental approaches\",\n      \"pmids\": [\"18794881\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"PTEN is a dual-specificity lipid/protein phosphatase that dephosphorylates PtdIns(3,4,5)P3 at the 3-position (antagonizing PI3K/AKT/mTOR signaling) and dephosphorylates protein substrates including PGK1 and PLK1; its activity, stability, and subcellular localization are regulated by an array of post-translational modifications (phosphorylation, acetylation by PCAF at K125/K128, poly-ADP-ribosylation by tankyrases leading to RNF146-mediated ubiquitination, deubiquitylation by USP13 and compartment-specific ubiquitylation by FBXO22 for nuclear PTEN, and S-nitrosylation via AMPK-eNOS), by protein interactions (p85/p110β complex, RPA1 at replication forks, TOP2A, AIF as oxidation protector), and by membrane association; in the nucleus PTEN promotes chromosome stability, DNA decatenation, and replication fork protection, while its transcription is regulated by p53 and by a feedback loop through Akt-EGR1-ARF, and its translation is controlled by mTOR/4E-BP1.\"\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\n```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1997,\n      \"finding\": \"PTEN was identified as a candidate tumor suppressor gene at chromosome 10q23, encoding a protein with a protein tyrosine phosphatase domain and extensive homology to the cytoskeletal protein tensin, suggesting it may suppress tumor growth by antagonizing protein tyrosine kinases and regulating focal adhesions.\",\n      \"method\": \"Positional cloning, homozygous deletion mapping, mutation screening in cancer cell lines\",\n      \"journal\": \"Science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — original cloning paper, replicated independently by MMAC1 identification\",\n      \"pmids\": [\"9072974\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"PTEN (MMAC1) encodes a protein with homology to the catalytic domain of protein phosphatases and to cytoskeletal proteins tensin and auxilin; mutations were identified in glioma, prostate, kidney, and breast carcinoma cell lines/specimens.\",\n      \"method\": \"Positional cloning, homozygous deletion mapping, sequence analysis\",\n      \"journal\": \"Nature genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — independent isolation of the same gene, orthogonal cloning strategy\",\n      \"pmids\": [\"9090379\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"TEP1 (identical to PTEN/MMAC1) possesses intrinsic protein tyrosine phosphatase activity; it is a cytoplasmic protein sharing homology with tensin and auxilin, and its expression is down-regulated by TGF-β.\",\n      \"method\": \"Biochemical phosphatase assay, immunofluorescence, Northern blot, chromosomal mapping\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — direct enzymatic activity demonstrated in vitro, subcellular localization by immunofluorescence\",\n      \"pmids\": [\"9187108\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"Germline mutations in PTEN cause Cowden disease; mutations are found throughout the gene and predicted to disrupt the protein tyrosine/dual-specificity phosphatase domain, establishing PTEN as a tumor suppressor in the germline.\",\n      \"method\": \"Germline mutational analysis of Cowden disease kindreds\",\n      \"journal\": \"Nature genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — germline mutation analysis in multiple families, replicated by multiple groups\",\n      \"pmids\": [\"9140396\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"PTEN dephosphorylates phosphatidylinositol 3,4,5-trisphosphate (PtdIns(3,4,5)P3) specifically at position 3 on the inositol ring; overexpression reduces insulin-induced PtdIns(3,4,5)P3, while the catalytically inactive C124S mutant causes PtdIns(3,4,5)P3 accumulation. PTEN also exhibits 3-phosphatase activity toward inositol 1,3,4,5-tetrakisphosphate.\",\n      \"method\": \"In vitro phosphatase assay with purified recombinant PTEN, transfection of wild-type and C124S mutant in 293 cells, lipid measurement\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — reconstituted in vitro with purified protein and active-site mutagenesis, foundational mechanism paper\",\n      \"pmids\": [\"9593664\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"The lipid phosphatase activity of PTEN is critical for its tumor suppressor function: a Cowden disease missense mutation (G129E) specifically ablates recognition of inositol phospholipid substrates without affecting protein phosphatase activity; wild-type PTEN expression in PTEN-deficient tumor cells inhibits PKB/Akt and regulates cell survival.\",\n      \"method\": \"In vitro lipid phosphatase assay, cell-based PIP3 measurement, PKB/Akt phosphorylation assay, ectopic expression in tumor cell lines\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — substrate-specific mutagenesis distinguishing lipid from protein phosphatase activity, functional rescue experiment\",\n      \"pmids\": [\"9811831\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"PTEN inhibits cell migration, integrin-mediated cell spreading, and the formation of focal adhesions; PTEN interacts with focal adhesion kinase (FAK) and reduces FAK tyrosine phosphorylation; overexpression of FAK partially antagonizes PTEN effects; the phosphatase domain is required for these effects.\",\n      \"method\": \"Cell migration assay, focal adhesion staining, co-immunoprecipitation, FAK phosphorylation assay, PTEN overexpression and antisense\",\n      \"journal\": \"Science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — multiple orthogonal functional assays with phosphatase-dead mutant control and reciprocal IP\",\n      \"pmids\": [\"9616126\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"Pten is essential for embryonic development; homozygous Pten knockout mice die early in embryogenesis; heterozygous mice develop hyperplastic-dysplastic changes and spontaneous tumors, demonstrating Pten is a bona fide tumor suppressor gene in vivo.\",\n      \"method\": \"Homologous recombination knockout in mice, histopathology, tumor analysis\",\n      \"journal\": \"Nature genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — in vivo mouse genetic model with rigorous phenotypic characterization, replicated by multiple labs\",\n      \"pmids\": [\"9697695\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"Crystal structure of PTEN reveals a phosphatase domain with an enlarged active site accommodating phosphoinositide substrates, and a C2 domain that binds phospholipid membranes in vitro; mutation of basic residues in the C2 domain reduces membrane affinity and tumor cell growth suppression.\",\n      \"method\": \"X-ray crystallography, lipid binding assay, mutagenesis, cell growth assay\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — crystal structure with functional validation by mutagenesis and membrane binding assay\",\n      \"pmids\": [\"10555148\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"PTEN directly dephosphorylates and inhibits focal adhesion kinase (FAK), thereby negatively regulating signals generated at focal adhesions; PTEN also inhibits the adaptor protein Shc to negatively regulate growth factor receptor signaling.\",\n      \"method\": \"In vitro phosphatase assay, co-immunoprecipitation, Western blot analysis of FAK phosphorylation\",\n      \"journal\": \"European journal of biochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 — review synthesizing experimental evidence, citing in vitro assays and co-IP from primary papers\",\n      \"pmids\": [\"10469123\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"PTEN PDZ binding domain (C-terminal) interacts with PDZ domains of hDLG and hMAST205; threonine phosphorylation of the PTEN PDZ binding domain inhibits interaction with hDLG and hMAST205 PDZ domains but promotes interaction with ~90 kDa and ~120 kDa proteins from cell lysates.\",\n      \"method\": \"Yeast two-hybrid, microtiter plate binding assay, peptide coprecipitation from cell lysates, Western blotting\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 — yeast two-hybrid plus cell lysate coprecipitation with phosphopeptide modulation\",\n      \"pmids\": [\"10646847\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"PTEN suppresses Bcl-2 expression via its lipid phosphatase activity acting through the Akt/CREB pathway; PTEN reduces Bcl-2 mRNA and protein, downregulates Bcl-2 promoter activity through decreased CREB phosphorylation at Ser133, and loss of PTEN leads to chemoresistance that is rescued by Bcl-2 overexpression.\",\n      \"method\": \"Transfection, RT-PCR, Western blot, Bcl-2 promoter-reporter assay, cell death assay\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal assays in single lab with lipid-phosphatase-dead mutant controls\",\n      \"pmids\": [\"11495901\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"p53 transcriptionally activates PTEN through a p53 binding element directly upstream of the PTEN gene; PTEN is required for p53-mediated apoptosis in immortalized mouse embryonic fibroblasts, placing PTEN downstream of p53 in a tumor suppressor signaling axis.\",\n      \"method\": \"Deletion and mutation analysis of PTEN promoter, p53 induction assays, mRNA measurement, apoptosis assay in PTEN-null MEFs\",\n      \"journal\": \"Molecular cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — promoter deletion/mutation analysis plus genetic epistasis in MEFs\",\n      \"pmids\": [\"11545734\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"PTEN is reversibly inactivated by H2O2 through formation of an intramolecular disulfide bond between the catalytic Cys124 and Cys71; thioredoxin, not glutaredoxin or glutathione, is the primary cellular reductant that restores PTEN activity; thioredoxin co-immunoprecipitates with PTEN from cell lysates.\",\n      \"method\": \"Purified PTEN oxidation assay, mass spectrometry of tryptic peptides, cysteine mutant analysis, co-immunoprecipitation, inhibitor studies in cells\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro biochemistry with mass spectrometry identification of disulfide, corroborated by co-IP and cell-based inhibitor studies\",\n      \"pmids\": [\"11916965\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"PTEN negatively regulates MDM2 transcription by suppressing its P1 promoter activity through its lipid phosphatase activity (independent of p53), thereby reducing L-Mdm2 expression and p90(MDM2) isoform production.\",\n      \"method\": \"Reporter assays, RT-PCR, Western blot, lipid phosphatase-dead PTEN mutant analysis, Pten-null cell lines and prostate cancer tissues\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — reporter assay with phosphatase-dead mutant controls in multiple cell contexts\",\n      \"pmids\": [\"15090541\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"PCAF histone acetyltransferase physically interacts with PTEN and acetylates Lys125 and Lys128 within the catalytic cleft of PTEN in a growth factor-dependent manner; acetylation of these residues inhibits PTEN's ability to down-regulate PI3K signaling and induce G1 cell cycle arrest; acetylation-resistant K125R/K128R PTEN mutants retain PI3K regulatory activity even with forced PCAF expression.\",\n      \"method\": \"Co-immunoprecipitation, acetylation assay, shRNA knockdown of PCAF, cell cycle analysis, PI3K signaling measurement, site-directed mutagenesis\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — physical interaction, enzymatic modification, mutagenesis of modification sites, and functional rescue, multiple orthogonal methods\",\n      \"pmids\": [\"16829519\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"Nuclear PTEN is essential for chromosomal integrity; PTEN localizes at centromeres and physically associates with CENP-C; disruption of Pten leads to centromere breakage and chromosomal translocations; PTEN regulates Rad51 expression to reduce spontaneous DNA double-strand breaks.\",\n      \"method\": \"Chromosome analysis, co-immunoprecipitation of PTEN with CENP-C, immunofluorescence localization, Rad51 expression analysis, Pten-null cells\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — physical association by co-IP, localization by immunofluorescence, and defined chromosomal phenotype in knockout cells\",\n      \"pmids\": [\"17218262\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"PTEN exists as a monomer or as part of a >600-kDa PTEN-associated complex (PAC); PTEN associates with p85, the regulatory subunit of PI3K, and the p110β isoform of PI3K; this association involves unphosphorylated PTEN within the PAC and is enhanced by trastuzumab treatment.\",\n      \"method\": \"Gel filtration, co-immunoprecipitation with specific antibodies, AKT phosphorylation assay, trastuzumab treatment\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 — gel filtration to define complex, reciprocal co-IP, functional correlation with AKT signaling\",\n      \"pmids\": [\"19635806\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"PTEN activity is regulated by its C-terminal tail phosphorylation: when phosphorylated, the unstructured C-terminal tail interacts with the phosphatase-C2 superdomain to inactivate PTEN by preventing membrane association; oxidation of the active site cysteine by ROS and C-terminal Ser/Thr phosphorylation inhibit PTEN and regulate its stability and localization.\",\n      \"method\": \"Biochemical assays, mutagenesis, membrane association assays, review of structural and regulatory data\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — synthesizes experimental data on mechanism of autoinhibition, backed by mutagenesis and membrane assays\",\n      \"pmids\": [\"18794881\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"PTEN enters the nucleus by multiple mechanisms including simple diffusion, active shuttling, cytoplasmic-localization-signal-dependent export, and monoubiquitylation-dependent import; nuclear PTEN has phosphatase-independent roles in chromosome stability, DNA repair, and cell cycle arrest distinct from cytoplasmic PTEN.\",\n      \"method\": \"Review of experimental data including nuclear localization studies, ubiquitylation assays, and chromosome stability assays\",\n      \"journal\": \"Journal of cell science\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 — review synthesizing direct experimental evidence on nuclear localization mechanisms and function\",\n      \"pmids\": [\"18216329\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"A novel Akt-EGR1-ARF-PTEN axis exists in which PTEN transcriptional activation requires p14ARF-mediated sumoylation of EGR1; Akt phosphorylates EGR1 at S350 and T309, promoting EGR1 interaction with ARF and subsequent sumoylation at K272; ARF-deficient mice exhibit reduced PTEN, establishing a regulatory circuit.\",\n      \"method\": \"In vivo sumoylation assay, co-immunoprecipitation, site-directed mutagenesis, ARF-null mouse analysis, Western blot\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — in vivo sumoylation, mutagenesis, and genetic model corroboration in single study\",\n      \"pmids\": [\"19057511\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"USP13 is a deubiquitylase that stabilizes PTEN by direct binding and deubiquitylation; USP13 loss in breast cancer cells promotes AKT phosphorylation and tumorigenesis through PTEN downregulation; USP13 overexpression suppresses tumorigenesis only in PTEN-positive cells.\",\n      \"method\": \"DUB screen (30 DUBs tested), co-immunoprecipitation, ubiquitylation assay, cell proliferation and tumor growth assays, human breast tumor correlation\",\n      \"journal\": \"Nature cell biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — systematic screen, direct binding, deubiquitylation assay, genetic functional validation in cells and in vivo\",\n      \"pmids\": [\"24270891\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Tankyrases (PARP family members) interact with PTEN, poly-ADP-ribosylate it, and promote its recognition by the PAR-binding E3 ubiquitin ligase RNF146, leading to PTEN ubiquitination and proteasomal degradation; tankyrase knockdown stabilizes PTEN and suppresses AKT signaling, cell proliferation, and tumor growth.\",\n      \"method\": \"Co-immunoprecipitation, ADP-ribosylation assay, ubiquitination assay, tankyrase knockdown, AKT phosphorylation assay, in vivo tumor model\",\n      \"journal\": \"Genes & development\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — new PTM identified with biochemical assays, E3 ligase identified, functional in vivo validation\",\n      \"pmids\": [\"25547115\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"PTEN is physically associated with replication protein A 1 (RPA1) via the RPA1 C-terminal domain; PTEN localizes at replication sites (shown by iPOND) and promotes RPA1 accumulation on replication forks; PTEN recruits the deubiquitinase OTUB1 to mediate RPA1 deubiquitination; PTEN deletion leads to replication fork collapse under hydroxyurea-induced stress.\",\n      \"method\": \"Co-immunoprecipitation, iPOND, STORM super-resolution imaging, deubiquitylation assay, replication fork analysis\",\n      \"journal\": \"Cell research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — multiple orthogonal methods (iPOND, STORM, co-IP, biochemical assay) in one study\",\n      \"pmids\": [\"26403191\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"AIF (apoptosis-inducing factor) physically interacts with PTEN and protects it from oxidation-mediated inactivation; PTEN is identified as a mitochondrial protein; AIF knockdown causes PTEN lipid phosphatase inactivation, AKT activation, and promotes epithelial-mesenchymal transition through β-catenin signaling.\",\n      \"method\": \"Co-immunoprecipitation, lipid phosphatase activity assay, oxidation assay, mitochondrial fractionation, in vitro and in vivo tumor metastasis models\",\n      \"journal\": \"EMBO reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — physical interaction, enzymatic activity measurement, subcellular fractionation, functional in vivo model\",\n      \"pmids\": [\"26415504\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"PTEN physically associates with TOP2A (DNA topoisomerase IIα) and stabilizes it through OTUD3 deubiquitinase; PTEN deficiency leads to TOP2A downregulation, dysfunction of the decatenation G2 checkpoint, and incomplete DNA decatenation causing ultra-fine anaphase bridges.\",\n      \"method\": \"Co-immunoprecipitation, ubiquitination assay, ultra-fine bridge (UFB) analysis, decatenation checkpoint assay, PTEN-null cell analysis\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — physical interaction by co-IP, enzymatic stability mechanism, defined chromosomal phenotype\",\n      \"pmids\": [\"26657567\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"PTEN physically associates with PLK1 (polo-like kinase 1) and reduces PLK1 phosphorylation in a protein phosphatase-dependent manner; PTEN deficiency leads to PLK1 hyperphosphorylation and polyploidy; a phospho-mimicking PLK1 mutant causes polyploidy, and a non-phosphorylatable PLK1 mutant rescues the polyploid phenotype.\",\n      \"method\": \"Co-immunoprecipitation, phosphatase assay, cell cycle analysis (polyploidy), site-directed mutagenesis of PLK1\",\n      \"journal\": \"Cell cycle\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — physical interaction, phosphatase-dependent functional change, genetic rescue with mutant PLK1\",\n      \"pmids\": [\"27398835\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"PARK2 depletion leads to AMPK-mediated activation of eNOS, increased reactive oxygen species and oxidized nitric oxide, resulting in PTEN inhibition by S-nitrosylation and subsequent ubiquitination; AMPK activation alone is sufficient to induce PTEN S-nitrosylation, linking energy stress to PTEN suppression.\",\n      \"method\": \"S-nitrosylation assay, AMPK activation, eNOS inhibition, ubiquitination assay, PI3K/Akt signaling measurement, in vivo cooperativity in Park2/Pten mouse model\",\n      \"journal\": \"Molecular cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — biochemical demonstration of S-nitrosylation, identification of upstream pathway, genetic validation in vivo\",\n      \"pmids\": [\"28306514\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"PTEN directly interacts with and dephosphorylates autophosphorylated PGK1 (at Y324) via its protein phosphatase activity, thereby inhibiting PGK1 kinase activity, glycolysis, and ATP production in brain tumor cells; PGK1-Y324F knockin mice show reduced brain tumor formation.\",\n      \"method\": \"Co-immunoprecipitation, in vitro phosphatase assay, PGK1 Y324 phosphorylation analysis, glycolysis measurement, knockin mouse model, human GBM specimen analysis\",\n      \"journal\": \"Molecular cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — direct substrate identification, in vitro reconstitution, mutagenesis, and in vivo knockin validation\",\n      \"pmids\": [\"31492635\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"PTEN inhibits ARID4B expression, while ARID4B is a transcriptional activator of PI3K subunit genes PIK3CA and PIK3R2; reciprocal binding of ARID4B and histone H1 to PIK3CA and PIK3R2 promoters modulates chromatin condensation; ARID4B is required for prostate tumorigenesis when PTEN is deficient.\",\n      \"method\": \"ChIP, promoter analysis, gene expression assays, functional tumorigenesis assays, patient cohort correlation\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — ChIP, functional tumorigenesis assays, mechanistic pathway identification in single study\",\n      \"pmids\": [\"31551414\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"FBXO22 induces ubiquitylation specifically of nuclear (not cytoplasmic) PTEN at lysine 221, targeting it for proteasomal degradation; FBXO22 acts as a tumor promoter by degrading nuclear PTEN, and is overexpressed in various cancer types.\",\n      \"method\": \"Co-immunoprecipitation, ubiquitylation assay, site-directed mutagenesis (K221), nuclear/cytoplasmic fractionation, functional tumor assays\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — specific ubiquitylation site identified by mutagenesis, compartment-specific effect established by fractionation, functional tumor assays\",\n      \"pmids\": [\"32249768\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"The carboxy-terminal tail (CTT) of PTEN, when phosphorylated, interacts with the phosphatase-C2 superdomain to prevent membrane association and inactivate the enzyme; alternate translation-initiation generates extended PTEN isoforms (e.g., PTEN-L) with a signal sequence, polyarginine motif, and membrane-binding helix that activates the enzyme and facilitates mitochondrial and nucleolar localization.\",\n      \"method\": \"Structural analysis, biochemical membrane association assays, isoform characterization, mutagenesis\",\n      \"journal\": \"Cold Spring Harbor perspectives in medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — structural and biochemical evidence for CTT autoinhibition; isoform characterization with functional annotation\",\n      \"pmids\": [\"31636093\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Physiological and oncogenic PI3K pathway activation increases PTEN expression via mTOR/4E-BP1-dependent translational control; deletion of 4E-BP1 abolishes this translational regulation; this constitutes a homeostatic feedback loop limiting pathway duration and contributing to rebound activation upon PI3K inhibitor treatment.\",\n      \"method\": \"PI3K inhibitor treatment, 4E-BP1 deletion, translational rate measurement, in vitro and in vivo PI3K signaling assays\",\n      \"journal\": \"Molecular cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic deletion of 4E-BP1 establishes mechanism, pharmacologic and oncogenic contexts tested\",\n      \"pmids\": [\"33606974\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Peroxiredoxin I (Prx I) directly interacts with PTEN and protects it from oxidation under mild oxidative stress, preserving PTEN tumor-suppressive function; Prx II-deficient cells show increased PTEN oxidation and insulin sensitivity; Prx III protects PTEN from oxidation by pro-oxidant lipid mediators.\",\n      \"method\": \"Co-immunoprecipitation, PTEN oxidation assay, Prx-deficient cell lines, insulin signaling measurement\",\n      \"journal\": \"Antioxidants\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 — direct physical interaction and enzymatic protection demonstrated, multiple Prx isoforms tested\",\n      \"pmids\": [\"33669370\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"PTEN overexpression in glioblastoma cells blocks G0/G1 to S phase progression by recruiting the CDK inhibitor p27Kip1 into cyclin E/CDK2 complexes, resulting in reduced CDK2 kinase activity and decreased phosphorylated retinoblastoma protein; CDK4 activity and p21Cip1 levels are unaffected.\",\n      \"method\": \"Adenoviral gene transfer, cell cycle analysis, CDK2 kinase assay, co-immunoprecipitation of p27Kip1 with cyclin E\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — cell cycle analysis with CDK kinase assay and co-IP demonstrating mechanism of G1 arrest\",\n      \"pmids\": [\"10344736\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"PTEN expression in glioma cells inhibits phospholipase C signaling (reducing intracellular IP3 and extracellular Ca2+ influx) and inhibits integrin-linked kinase (ILK) activity through its catalytic activity; AKT3 (highly expressed in brain) is identified as a target for PTEN repression.\",\n      \"method\": \"IP3 measurement, Ca2+ influx assay, ILK activity assay, PTEN overexpression, catalytic mutant control\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple downstream pathway assays with catalytic mutant controls\",\n      \"pmids\": [\"10644997\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"PTEN is a dual-specificity lipid and protein phosphatase that primarily dephosphorylates PtdIns(3,4,5)P3 at the 3-position to antagonize PI3K/AKT signaling, while also directly dephosphorylating protein substrates including FAK, PGK1, and PLK1; its activity is regulated by C-terminal tail phosphorylation (autoinhibition via prevention of membrane association), reversible oxidation of the Cys124/Cys71 active site disulfide, and multiple post-translational modifications including acetylation (by PCAF at Lys125/128), poly-ADP-ribosylation (by tankyrases targeting it for RNF146-mediated ubiquitination and degradation), deubiquitylation (by USP13 for stabilization), S-nitrosylation (downstream of eNOS/AMPK), and compartment-specific ubiquitylation (nuclear PTEN at Lys221 by FBXO22); in the nucleus, PTEN associates with centromeres via CENP-C to maintain chromosomal stability, promotes RPA1 stability at replication forks, and stabilizes TOP2A for DNA decatenation, while cytoplasmic PTEN suppresses cell migration through FAK dephosphorylation, inhibits glycolysis through PGK1 dephosphorylation, and is transcriptionally induced by p53; pathway homeostasis is further maintained by mTOR/4E-BP1-dependent translational upregulation of PTEN upon PI3K activation.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"PTEN is a dual-specificity phosphatase that serves as the principal negative regulator of PI3K/AKT signaling by dephosphorylating PtdIns(3,4,5)P3 at the D3 position of the inositol ring, and additionally acts as a protein phosphatase toward substrates including PGK1 (at Y324) and PLK1, thereby suppressing glycolysis and maintaining mitotic fidelity [PMID:9593664, PMID:31492635, PMID:27398835]. PTEN stability and activity are governed by a convergent network of post-translational modifications: PCAF-mediated acetylation of K125/K128 within the catalytic cleft inhibits lipid phosphatase activity, tankyrase-catalyzed poly-ADP-ribosylation promotes RNF146-dependent ubiquitination and degradation, USP13-mediated deubiquitylation stabilizes the protein, FBXO22 selectively ubiquitylates nuclear PTEN at K221, and S-nitrosylation downstream of AMPK–eNOS inactivates PTEN under oxidative or PARK2-deficient conditions [PMID:16829519, PMID:25547115, PMID:24270891, PMID:32249768, PMID:28306514]. In the nucleus, PTEN localizes to replication forks via RPA1 interaction to recruit OTUB1 for fork protection, stabilizes TOP2A through OTUD3 to ensure proper DNA decatenation, and promotes chromosome integrity during mitosis [PMID:26403191, PMID:26657567]. PTEN expression is itself subject to feedback control: p53 directly transactivates the PTEN promoter, an Akt–EGR1–ARF axis sustains its transcription, and mTOR/4E-BP1-dependent translational upregulation provides homeostatic buffering against PI3K pathway hyperactivation [PMID:11545734, PMID:19057511, PMID:33606974].\",\n  \"teleology\": [\n    {\n      \"year\": 1997,\n      \"claim\": \"Establishing that PTEN possesses intrinsic phosphatase activity resolved its biochemical identity as an enzyme rather than merely a tumor-suppressor scaffold.\",\n      \"evidence\": \"Biochemical phosphatase assay and immunofluorescence localization of cloned TEP1/PTEN\",\n      \"pmids\": [\"9187108\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Physiological substrates unknown\", \"Lipid vs. protein substrate preference unresolved\"]\n    },\n    {\n      \"year\": 1998,\n      \"claim\": \"Demonstrating that PTEN dephosphorylates PtdIns(3,4,5)P3 specifically at the 3-position identified its principal substrate and established the mechanistic basis for PI3K pathway antagonism.\",\n      \"evidence\": \"In vitro lipid phosphatase assay with purified recombinant PTEN and C124S catalytic-dead mutant in 293 cells\",\n      \"pmids\": [\"9593664\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How PTEN accesses membrane-embedded substrate in vivo was unclear\", \"Protein phosphatase substrates remained unidentified\"]\n    },\n    {\n      \"year\": 1999,\n      \"claim\": \"Linking PTEN to G1 arrest via p27Kip1 recruitment into cyclin E/CDK2 complexes connected lipid phosphatase activity to a defined cell-cycle control mechanism.\",\n      \"evidence\": \"Adenoviral PTEN overexpression in PTEN-null glioblastoma cells with CDK2 kinase assay and p27 co-IP\",\n      \"pmids\": [\"10344736\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether PTEN directly or indirectly increases p27 association was not resolved\", \"Contribution of protein phosphatase vs. lipid phosphatase activity was not separated\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Identification of PDZ-domain partners (hDLG, hMAST205) and the bidirectional regulation of interactions by C-terminal phosphorylation revealed a phospho-switch controlling PTEN scaffolding.\",\n      \"evidence\": \"Yeast two-hybrid and peptide coprecipitation with phospho/dephospho PTEN C-terminal peptides\",\n      \"pmids\": [\"10646847\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Functional consequences of hDLG/hMAST205 binding for PTEN activity or localization not established\", \"Identity of ~90 and ~120 kDa co-precipitating proteins unknown\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Discovery that p53 directly transactivates the PTEN promoter and that PTEN is required for p53-dependent apoptosis established a transcriptional axis linking the two major tumor suppressors.\",\n      \"evidence\": \"PTEN promoter deletion/mutation analysis, p53 induction in multiple cell types, PTEN-KO MEFs with apoptosis readout\",\n      \"pmids\": [\"11545734\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether other transcription factors cooperate with p53 at the PTEN promoter was unresolved\", \"Mechanism by which PTEN executes p53-dependent apoptosis not fully delineated\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Identification of PCAF-mediated acetylation at K125/K128 as an inhibitory modification of PTEN's catalytic cleft revealed the first direct enzymatic post-translational silencing mechanism of PTEN phosphatase activity.\",\n      \"evidence\": \"Co-IP, in vitro acetylation assay, acetylation-resistant K125R/K128R mutants with lipid phosphatase and cell-cycle readouts\",\n      \"pmids\": [\"16829519\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Deacetylase(s) responsible for reversing K125/K128 acetylation not identified\", \"In vivo acetylation stoichiometry unknown\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Elucidation of multiple nuclear-entry mechanisms (diffusion, monoubiquitylation-dependent import, CLS-dependent export) and interfacial membrane-binding requirements unified the spatial regulation of PTEN across compartments.\",\n      \"evidence\": \"Monoubiquitylation-dependent nuclear import experiments, membrane binding assays with PtdIns(4,5)P2 and phosphatidylserine, oxidation and phosphorylation effects on localization\",\n      \"pmids\": [\"18216329\", \"18794881\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Specific E3 ligase for monoubiquitylation-dependent nuclear import debated\", \"Quantitative partitioning between nuclear and cytoplasmic pools not established in primary tissues\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Defining the Akt–EGR1–ARF feedback loop for PTEN transcription showed that PI3K pathway output homeostatically feeds back to boost PTEN levels, adding a transcriptional layer to PTEN regulation.\",\n      \"evidence\": \"In vivo sumoylation assay, Akt phosphorylation-site EGR1 mutants, ARF-knockout mouse, PTEN promoter reporter\",\n      \"pmids\": [\"19057511\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether the ARF-mediated sumoylation of EGR1 operates identically in non-fibroblast lineages was untested\", \"Quantitative contribution of this axis relative to p53-driven transcription unclear\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Discovery of the >600 kDa PTEN-associated complex with p85/p110β revealed that PTEN is not merely an enzyme opposing PI3K products but physically engages the PI3K holoenzyme, suggesting direct substrate channeling or regulation.\",\n      \"evidence\": \"Co-IP with phospho-state-specific PTEN antibodies, gel filtration of endogenous complex, trastuzumab modulation\",\n      \"pmids\": [\"19635806\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether the PAC complex serves a catalytic channeling function or a regulatory scaffolding function was not determined\", \"Stoichiometry and structural basis of the complex unknown\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Identification of USP13 as a PTEN deubiquitylase that stabilizes PTEN protein levels established deubiquitylation as a tumor-suppressive mechanism controlling PTEN abundance.\",\n      \"evidence\": \"DUB screen of 30 enzymes, Co-IP, deubiquitylation assay, USP13 knockdown with AKT and tumor growth readouts in vitro and in vivo\",\n      \"pmids\": [\"24270891\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Specific ubiquitin chain types removed by USP13 not characterized\", \"Whether USP13 acts on nuclear vs. cytoplasmic PTEN pools differentially unknown\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Discovery that tankyrases PARylate PTEN to trigger RNF146-dependent ubiquitination and degradation identified a druggable pathway for PTEN stabilization.\",\n      \"evidence\": \"Co-IP, ADP-ribosylation assay, RNF146 recognition of PARylated PTEN, tankyrase1/2 double knockdown stabilizing PTEN with suppressed AKT in vitro and in vivo\",\n      \"pmids\": [\"25547115\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Specific PARylation sites on PTEN not mapped\", \"Whether tankyrase inhibitors can restore PTEN in tumors with partial PTEN loss not tested\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Demonstrating that PTEN localizes to replication forks, interacts with RPA1, and recruits OTUB1 to protect stalled forks revealed a lipid-phosphatase-independent genome-maintenance function.\",\n      \"evidence\": \"iPOND, STORM super-resolution microscopy, Co-IP with RPA1, OTUB1 interaction, PTEN-KO fork collapse phenotype upon hydroxyurea\",\n      \"pmids\": [\"26403191\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether PTEN's phosphatase activity is required at replication forks was not separated from its scaffolding role\", \"Interplay between RPA1-bound PTEN and the ATR checkpoint pathway not explored\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Identification of PTEN–TOP2A interaction and OTUD3-mediated TOP2A stabilization linked PTEN loss to decatenation checkpoint failure and ultra-fine bridge formation, explaining chromosome segregation defects in PTEN-null cells.\",\n      \"evidence\": \"Co-IP, ubiquitination assay, PTEN-KO with UFB microscopy, decatenation checkpoint readout\",\n      \"pmids\": [\"26657567\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether PTEN directly recruits OTUD3 to TOP2A or acts indirectly was not resolved\", \"Single study; independent replication lacking\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Demonstration that PTEN dephosphorylates PLK1 as a protein phosphatase substrate, with loss of PTEN causing PLK1 hyperphosphorylation and polyploidy, extended the catalog of protein substrates beyond lipids.\",\n      \"evidence\": \"Co-IP, phosphatase assay, PTEN-KO chromosome content analysis, PLK1 non-phosphorylatable mutant rescue\",\n      \"pmids\": [\"27398835\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Specific PLK1 phospho-site(s) targeted by PTEN not mapped\", \"Single lab finding awaiting independent confirmation\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Showing that PARK2 loss activates AMPK–eNOS–mediated S-nitrosylation of PTEN established a redox-based inactivation pathway cooperating with genetic PTEN loss in tumorigenesis.\",\n      \"evidence\": \"PARK2 KO, eNOS inhibition, S-nitrosylation detection, AKT readouts, compound Park2/Pten-deficient mice with accelerated tumorigenesis\",\n      \"pmids\": [\"28306514\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Specific cysteine residue(s) S-nitrosylated on PTEN not mapped\", \"Reversibility and kinetics of S-nitrosylation in vivo unknown\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Identification of PGK1 Y324 as a direct protein phosphatase substrate of PTEN, validated by knockin mouse, provided the most rigorous in vivo proof that PTEN's protein phosphatase activity controls glycolysis and tumor metabolism.\",\n      \"evidence\": \"In vitro phosphatase assay, Co-IP, PGK1 Y324F knockin mouse, human GBM correlation of PGK1-pY324 with PTEN status\",\n      \"pmids\": [\"31492635\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether PGK1 dephosphorylation contributes to tumor suppression independently of lipid phosphatase activity in vivo not genetically separated\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Discovery that FBXO22 ubiquitylates nuclear PTEN specifically at K221 for proteasomal degradation explained the selective instability of the nuclear pool and identified a compartment-specific regulatory E3 ligase.\",\n      \"evidence\": \"Ubiquitylation assay, K221 mutagenesis, FBXO22 knockdown/overexpression, nuclear–cytoplasmic fractionation, colorectal cancer tissue analysis\",\n      \"pmids\": [\"32249768\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Signals that activate FBXO22-dependent nuclear PTEN degradation in cancer not identified\", \"Whether FBXO22 competes with monoubiquitylation-dependent nuclear import unclear\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Establishing mTOR/4E-BP1-dependent translational upregulation of PTEN as a homeostatic feedback mechanism closed the loop between PI3K output and PTEN protein levels at the translational level.\",\n      \"evidence\": \"4E-BP1 genetic deletion, mTOR inhibitor treatment, translational reporters, PI3K modulation\",\n      \"pmids\": [\"33606974\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Specific cis-regulatory elements in PTEN mRNA mediating 4E-BP1-dependent translation not mapped\", \"How this feedback is disrupted in tumors retaining PTEN genomic locus but losing protein unclear\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How the lipid phosphatase and protein phosphatase activities of PTEN are coordinately regulated in vivo, and which activity is the dominant tumor-suppressive function in each tissue context, remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No separation-of-function knockin model distinguishing lipid vs. protein phosphatase activity in tumorigenesis\", \"Structural basis for how acetylation, PARylation, and S-nitrosylation differentially affect the two activities unknown\", \"Complete inventory of direct protein substrates lacking\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0016787\", \"supporting_discovery_ids\": [0, 1, 13, 12]},\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [1, 12, 13]},\n      {\"term_id\": \"GO:0008289\", \"supporting_discovery_ids\": [0, 23]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [1]},\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [5, 17, 10, 11]},\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [23]},\n      {\"term_id\": \"GO:0005783\", \"supporting_discovery_ids\": [22]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [0, 9, 19, 20]},\n      {\"term_id\": \"R-HSA-5357801\", \"supporting_discovery_ids\": [2, 22]},\n      {\"term_id\": \"R-HSA-1640170\", \"supporting_discovery_ids\": [19, 12]},\n      {\"term_id\": \"R-HSA-73894\", \"supporting_discovery_ids\": [10, 11]},\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [2, 14, 16]}\n    ],\n    \"complexes\": [\n      \"PTEN-associated complex (PAC; with p85/p110β)\"\n    ],\n    \"partners\": [\n      \"RPA1\",\n      \"TOP2A\",\n      \"PLK1\",\n      \"PGK1\",\n      \"USP13\",\n      \"PCAF\",\n      \"TNKS\",\n      \"FBXO22\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\n```json\n{\n  \"mechanistic_narrative\": \"PTEN is a dual-specificity phosphatase that functions as a major tumor suppressor by dephosphorylating phosphatidylinositol 3,4,5-trisphosphate (PIP3) at the D3 position, thereby antagonizing PI3K/AKT signaling to control cell survival, proliferation, and metabolism [PMID:9593664, PMID:9811831]. Beyond its lipid phosphatase activity, PTEN directly dephosphorylates protein substrates including FAK (suppressing cell migration), PGK1 (inhibiting glycolysis), and PLK1 (preventing polyploidy), and it maintains genomic integrity through nuclear functions that include centromere association via CENP-C, stabilization of RPA1 at replication forks, and promotion of TOP2A-dependent DNA decatenation [PMID:9616126, PMID:31492635, PMID:17218262, PMID:26403191, PMID:26657567]. PTEN activity is regulated by C-terminal tail phosphorylation-dependent autoinhibition, reversible oxidative inactivation through a Cys124–Cys71 disulfide, acetylation at Lys125/128 by PCAF, S-nitrosylation downstream of AMPK/eNOS, tankyrase-mediated PARylation leading to RNF146-dependent degradation, stabilization by the deubiquitinase USP13, and compartment-specific nuclear degradation by the E3 ligase FBXO22 at Lys221 [PMID:18794881, PMID:11916965, PMID:16829519, PMID:28306514, PMID:25547115, PMID:24270891, PMID:32249768]. Germline PTEN mutations cause Cowden disease, a cancer predisposition syndrome [PMID:9140396].\",\n  \"teleology\": [\n    {\n      \"year\": 1997,\n      \"claim\": \"Positional cloning at 10q23 identified PTEN as a candidate tumor suppressor with a protein phosphatase domain, resolving the identity of a frequently deleted locus in diverse cancers and establishing a phosphatase-based tumor suppression paradigm.\",\n      \"evidence\": \"Homozygous deletion mapping and mutation screening in cancer cell lines by two independent groups\",\n      \"pmids\": [\"9072974\", \"9090379\", \"9187108\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Physiological substrates unknown\", \"Lipid phosphatase activity not yet recognized\", \"In vivo tumor suppressor function not formally tested\"]\n    },\n    {\n      \"year\": 1997,\n      \"claim\": \"Discovery that germline PTEN mutations cause Cowden disease established PTEN as a bona fide hereditary tumor suppressor, linking its phosphatase domain to human cancer predisposition.\",\n      \"evidence\": \"Germline mutational analysis of multiple Cowden disease kindreds\",\n      \"pmids\": [\"9140396\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Genotype–phenotype correlations for specific mutations unresolved\", \"Whether protein or lipid phosphatase activity is critical for tumor suppression unknown\"]\n    },\n    {\n      \"year\": 1998,\n      \"claim\": \"Identification of PIP3 as the primary physiological substrate of PTEN, with D3-specific dephosphorylation, transformed understanding from a protein phosphatase to a lipid phosphatase that directly antagonizes PI3K signaling and controls AKT activation.\",\n      \"evidence\": \"In vitro phosphatase assay with purified recombinant PTEN, active-site C124S mutagenesis, cellular PIP3 measurement; Cowden mutation G129E selectively ablating lipid but not protein phosphatase activity\",\n      \"pmids\": [\"9593664\", \"9811831\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis for PIP3 recognition unresolved\", \"Relative contribution of protein vs. lipid phosphatase activity to each tumor suppressor function unclear\"]\n    },\n    {\n      \"year\": 1998,\n      \"claim\": \"Demonstration that PTEN suppresses cell migration by dephosphorylating FAK and inhibiting focal adhesion formation revealed a protein phosphatase-dependent function distinct from lipid phosphatase activity, establishing PTEN as a dual-function enzyme.\",\n      \"evidence\": \"Cell migration and focal adhesion assays, co-immunoprecipitation with FAK, phosphatase-dead mutant controls\",\n      \"pmids\": [\"9616126\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether FAK dephosphorylation occurs in vivo at physiological PTEN levels not established\", \"Relative importance of FAK vs. PIP3 regulation for tumor suppression unclear\"]\n    },\n    {\n      \"year\": 1998,\n      \"claim\": \"Pten knockout mice confirmed essential developmental and tumor-suppressive roles in vivo, with embryonic lethality in homozygotes and spontaneous tumors in heterozygotes, validating the haploinsufficient tumor suppressor model.\",\n      \"evidence\": \"Homologous recombination knockout in mice, histopathology, tumor spectrum analysis\",\n      \"pmids\": [\"9697695\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Tissue-specific contributions of PTEN loss not dissected\", \"Nuclear vs. cytoplasmic functions not distinguished in vivo\"]\n    },\n    {\n      \"year\": 1999,\n      \"claim\": \"The crystal structure revealed an enlarged active-site pocket accommodating PIP3 and a C2 domain mediating membrane recruitment, providing the structural basis for substrate specificity and explaining how cancer-associated mutations impair function.\",\n      \"evidence\": \"X-ray crystallography, lipid binding assay, C2 domain mutagenesis, cell growth suppression assay\",\n      \"pmids\": [\"10555148\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Full-length PTEN structure including C-terminal tail not resolved\", \"Membrane-bound catalytic conformation unknown\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Identification of p53 as a direct transcriptional activator of PTEN, with PTEN required for p53-mediated apoptosis, established a tumor suppressor signaling axis linking the two most frequently inactivated genes in cancer.\",\n      \"evidence\": \"PTEN promoter deletion and mutation analysis, p53 induction, apoptosis in PTEN-null MEFs\",\n      \"pmids\": [\"11545734\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether p53-PTEN axis operates equivalently in all tissue contexts unknown\", \"Post-translational crosstalk beyond transcription not addressed\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Discovery of reversible oxidative inactivation through a Cys124–Cys71 disulfide bond, reactivated by thioredoxin, revealed that ROS directly regulate PTEN and link redox signaling to PI3K pathway activation.\",\n      \"evidence\": \"Purified PTEN oxidation, mass spectrometry of disulfide, cysteine mutant analysis, co-IP with thioredoxin, cell-based inhibitor studies\",\n      \"pmids\": [\"11916965\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Quantitative contribution of oxidative inactivation to PTEN regulation in specific tissues unknown\", \"Role of other reductases in vivo not fully excluded\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Identification of PCAF-mediated acetylation at Lys125/128 within the catalytic cleft as an inhibitory modification demonstrated a growth-factor-responsive epigenetic switch that tunes PTEN activity independently of protein levels.\",\n      \"evidence\": \"Co-IP, acetylation assay, PCAF shRNA, acetylation-resistant K125R/K128R mutagenesis, PI3K signaling and cell cycle analysis\",\n      \"pmids\": [\"16829519\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Identity of the deacetylase that reverses this modification not established\", \"In vivo significance in tumorigenesis not tested\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Nuclear PTEN was shown to associate with centromeres through CENP-C and maintain chromosomal stability independently of lipid phosphatase activity, establishing a phosphatase-independent genome guardian role.\",\n      \"evidence\": \"Co-immunoprecipitation of PTEN with CENP-C, immunofluorescence at centromeres, chromosome breakage analysis in Pten-null cells\",\n      \"pmids\": [\"17218262\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether CENP-C interaction is direct or bridged unknown\", \"Mechanism by which PTEN at centromeres prevents breakage not molecularly defined\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Identification of USP13 as a PTEN-stabilizing deubiquitinase established that PTEN protein levels are actively maintained by deubiquitylation, providing a mechanism for PTEN downregulation in cancers without genomic loss.\",\n      \"evidence\": \"Systematic DUB screen, direct binding by co-IP, ubiquitylation assay, tumor suppression only in PTEN-positive cells\",\n      \"pmids\": [\"24270891\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Which E3 ligase ubiquitylates PTEN in this context not identified\", \"Tissue specificity of USP13-PTEN axis not resolved\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Discovery that tankyrases PARylate PTEN to promote RNF146-mediated ubiquitination and degradation revealed a PARP-dependent proteolytic mechanism for PTEN turnover, connecting poly-ADP-ribosylation to PI3K/AKT signaling control.\",\n      \"evidence\": \"Co-IP, ADP-ribosylation assay, ubiquitination assay, tankyrase knockdown, AKT signaling, in vivo tumor model\",\n      \"pmids\": [\"25547115\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Specific PARylation sites on PTEN not mapped\", \"Interplay between tankyrase-mediated degradation and USP13-mediated stabilization not quantified\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"PTEN was shown to localize at replication forks, stabilize RPA1 through OTUB1-mediated deubiquitination, and maintain fork integrity under replication stress, extending its genome-protective role to DNA replication.\",\n      \"evidence\": \"iPOND, STORM super-resolution imaging, co-IP with RPA1, deubiquitylation assay, hydroxyurea-induced replication stress\",\n      \"pmids\": [\"26403191\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether PTEN phosphatase activity is required for replication fork protection unclear\", \"How PTEN is recruited to forks not defined\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"PTEN S-nitrosylation downstream of AMPK-activated eNOS was identified as a mechanism linking metabolic/energy stress to PTEN inactivation and subsequent PI3K pathway activation, mediated by PARK2 deficiency.\",\n      \"evidence\": \"S-nitrosylation assay, AMPK activation, eNOS inhibition, ubiquitination assay, genetic validation in Park2/Pten compound mouse model\",\n      \"pmids\": [\"28306514\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Specific cysteine residue(s) targeted by S-nitrosylation not fully resolved\", \"Whether this mechanism operates outside Parkinson's-related contexts not established\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Direct dephosphorylation of PGK1 at Y324 by PTEN's protein phosphatase activity was shown to suppress glycolysis and brain tumorigenesis, establishing a metabolic tumor suppressor function distinct from PIP3 regulation.\",\n      \"evidence\": \"In vitro phosphatase assay, co-IP, glycolysis measurement, PGK1-Y324F knockin mouse, human GBM specimen analysis\",\n      \"pmids\": [\"31492635\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether PGK1 dephosphorylation contributes to tumor suppression outside brain not tested\", \"Full scope of PTEN protein substrates in metabolism not surveyed\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"FBXO22 was identified as a compartment-specific E3 ligase that ubiquitylates nuclear PTEN at Lys221 for proteasomal degradation, resolving how nuclear and cytoplasmic PTEN pools are differentially regulated.\",\n      \"evidence\": \"Co-IP, ubiquitylation assay, K221 mutagenesis, nuclear/cytoplasmic fractionation, functional tumor assays\",\n      \"pmids\": [\"32249768\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Signals that trigger FBXO22-mediated nuclear PTEN degradation not defined\", \"Interplay with monoubiquitylation-dependent nuclear import unclear\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"A homeostatic feedback loop was identified in which PI3K activation increases PTEN translation through mTOR/4E-BP1, explaining pathway self-limitation and rebound signaling upon PI3K inhibitor withdrawal.\",\n      \"evidence\": \"4E-BP1 genetic deletion, translational rate measurement, pharmacologic PI3K inhibition, in vitro and in vivo signaling assays\",\n      \"pmids\": [\"33606974\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether other translational regulators cooperate with 4E-BP1 for PTEN mRNA not tested\", \"Clinical implications for PI3K inhibitor resistance not mechanistically validated\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key unresolved questions include the full-length membrane-engaged PTEN structure, the complete inventory of direct protein substrates, the quantitative interplay among competing PTMs (phosphorylation, ubiquitylation, acetylation, PARylation, S-nitrosylation, oxidation) in specific tissue and signaling contexts, and how nuclear versus cytoplasmic PTEN pools are coordinately regulated to balance genome integrity and PI3K signaling functions.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Full-length PTEN structure with C-terminal tail and membrane not resolved\", \"Systematic identification of protein phosphatase substrates incomplete\", \"Quantitative modeling of competing PTM inputs not achieved\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [2, 6, 9, 26, 28]},\n      {\"term_id\": \"GO:0016787\", \"supporting_discovery_ids\": [4, 5, 8]},\n      {\"term_id\": \"GO:0008289\", \"supporting_discovery_ids\": [4, 5, 8]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [4, 5, 11, 32]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [2, 17, 31]},\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [16, 19, 30]},\n      {\"term_id\": \"GO:0005694\", \"supporting_discovery_ids\": [16]},\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [8, 18, 31]},\n      {\"term_id\": \"GO:0005739\", \"supporting_discovery_ids\": [24]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [4, 5, 11, 32, 35]},\n      {\"term_id\": \"R-HSA-1640170\", \"supporting_discovery_ids\": [26, 34]},\n      {\"term_id\": \"R-HSA-5357801\", \"supporting_discovery_ids\": [11, 12]},\n      {\"term_id\": \"R-HSA-73894\", \"supporting_discovery_ids\": [16, 23]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [0, 1, 3, 7]},\n      {\"term_id\": \"R-HSA-392499\", \"supporting_discovery_ids\": [21, 22, 30]},\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [28]}\n    ],\n    \"complexes\": [\n      \"PTEN-associated complex (PAC, >600 kDa)\"\n    ],\n    \"partners\": [\n      \"FAK\",\n      \"CENP-C\",\n      \"RPA1\",\n      \"TOP2A\",\n      \"PLK1\",\n      \"PGK1\",\n      \"USP13\",\n      \"PCAF\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}